[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 131
1. Shayanfar N, Mashayekh M, Mohammadpour M: Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma. Acta Med Iran; 2010 May-Jun;48(3):142-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma.
  • The aim of present study is to evaluate the status of progesterone receptor (PR) and proliferation marker Ki67 in various grades of meningioma in a group of Iranian patients.
  • 78 cases of meningioma were selected from the file of a hospital university.
  • PR were positive in 61/63 (96.8%) of grade I tumors, 2/10 (20%) of grade II, and 0/5 (0%) of grade III tumors.
  • Ki67 LI was %2.98 +/- 2.27 in grade I tumors, %9.30 +/- 5.79 in grade II tumors and %34.00 +/- 5.47 in grade III tumors.
  • For both markers, differences between grade I, II and III tumors were significant (P < 0.001).
  • There was a reverse relationship between mean of Ki67 LI and PR status, with increasing grade of tumor.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Iran. Male. Middle Aged. Neoplasm Staging. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137648.001).
  • [ISSN] 0044-6025
  • [Journal-full-title] Acta medica Iranica
  • [ISO-abbreviation] Acta Med Iran
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Progesterone
  •  go-up   go-down


2. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res; 2010 Aug 15;16(16):4155-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
  • EXPERIMENTAL DESIGN: We identified genetic alterations associated with histologic progression of 36 paired meningioma samples in 18 patients using 500K SNP genotyping arrays and NF2 gene sequencing.
  • RESULTS: The most frequent chromosome alterations observed in progressing meningioma samples are early alterations (i.e., present both in lower- and higher-grade samples of a single patient).
  • In our series, NF2 gene inactivation was an early and frequent event in progressing meningioma samples (73%).
  • Chromosome alterations acquired during progression from grade I to grade II meningioma were not recurrent.
  • Progression to grade III was characterized by recurrent genomic alterations, the most frequent being CDKN2A/CDKN2B locus loss on 9p.
  • This pattern of alterations could thus be used as markers in clinical practice to identify tumors prone to progress among grade I meningiomas.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Dosage. Gene Expression. Gene Expression Profiling. Genotype. Humans. Loss of Heterozygosity. Male. Middle Aged. Mutation. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682713.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Lui PC, Chau TK, Wong SS, Lau PP, Tse GM, Thomas TM, Ng HK: Cytology of chordoid meningioma: a series of five cases with emphasis on differential diagnoses. J Clin Pathol; 2007 Sep;60(9):1024-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of chordoid meningioma: a series of five cases with emphasis on differential diagnoses.
  • BACKGROUND: Chordoid meningioma is a rare meningioma variant characterised by epithelioid cord-like tumour cells in a myxoid stroma.
  • It is classified as grade II (World Health Organization) tumours, as they have a tendency to behave more aggressively than traditional meningiomas and have a greater likelihood of recurrence.
  • AIMS: To report the features of intraoperative imprint smears of five cases of chordoid meningioma.
  • [MeSH-minor] Adult. Aged. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Intranuclear Inclusion Bodies / pathology. Intraoperative Care / methods. Magnetic Resonance Imaging. Male. Middle Aged. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):259-63 [15085764.001]
  • [Cites] Neurosurgery. 1991 Oct;29(4):575-9 [1944839.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):331-4 [8191821.001]
  • [Cites] Acta Cytol. 1995 Jul-Aug;39(4):693-7 [7543235.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):614-8 [9622677.001]
  • [Cites] Acta Cytol. 1999 Mar-Apr;43(2):252-6 [10097720.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):454-8 [10470821.001]
  • [Cites] Clin Neuropathol. 2004 Sep-Oct;23(5):232-7 [15581026.001]
  • [Cites] Virchows Arch. 2005 Mar;446(3):333-7 [15714337.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):899-905 [10895812.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1330-42 [12360048.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Mar;61(1):91-4 [12715027.001]
  • [Cites] Ann Pathol. 2003 Feb;23(1):76-8 [12743508.001]
  • [Cites] J Korean Med Sci. 2003 Oct;18(5):768-71 [14555838.001]
  • [Cites] Ultrastruct Pathol. 2003 Sep-Oct;27(5):363-8 [14708728.001]
  • [Cites] Neurol India. 2003 Dec;51(4):522-4 [14742937.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):243-7 [15484703.001]
  • [Cites] Acta Cytol. 2004 May-Jun;48(3):397-401 [15192958.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):391-406 [3383139.001]
  • (PMID = 16837627.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1972413
  •  go-up   go-down


Advertisement
4. Binello E, Bederson JB, Kleinman GM: Hemangiopericytoma: collision with meningioma and recurrence. Neurol Sci; 2010 Oct;31(5):625-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytoma: collision with meningioma and recurrence.
  • This report provides the first documentation in the literature of a hemangiopericytoma colliding with a meningioma, and recurring after treatment with gross total resection.
  • Results were classically representative of a hemangiopericytoma (World Health Organization grade II) and of a meningioma (World Health Organization grade I).
  • [MeSH-major] Brain Neoplasms / complications. Hemangiopericytoma / complications. Meningeal Neoplasms / complications. Meningioma / complications. Neoplasm Recurrence, Local / complications
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Humans. Magnetic Resonance Imaging. Male. Recurrence

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1996;138(12):1399-408 [9030346.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Histopathology. 1996 Jul;29(1):57-61 [8818695.001]
  • [Cites] Surg Neurol. 1990 Feb;33(2):139-41 [2154868.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14 (5):e14 [15669810.001]
  • [Cites] Hum Pathol. 1991 Jan;22(1):84-91 [1985083.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Nov;38(11):733-7 [9919906.001]
  • [Cites] Cancer. 1954 May;7(3):602-6 [13160944.001]
  • [Cites] Ultrastruct Pathol. 1989 Mar-Jun;13(2-3):111-54 [2734855.001]
  • [Cites] Surg Neurol. 2003 Jan;59(1):47-53; discussion 53-4 [12633961.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1491-7 [15042684.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(6):575-86 [11534674.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Surg Neurol. 2006 Sep;66(3):324-7; discussion 327 [16935649.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):37-41 [7802136.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] Am J Clin Pathol. 1978 Sep;70(3):375-80 [707404.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Clin Neuropathol. 1988 May-Jun;7(3):93-9 [3060290.001]
  • [Cites] Neurosurgery. 1981 Jan;8(1):20-5 [6259551.001]
  • [Cites] Neurosurgery. 2001 Jun;48(6):1358-61 [11383742.001]
  • [Cites] Cancer. 1998 May 15;82(10):1915-20 [9587125.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):514-22 [2797389.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Aug;17(7):1365-71 [8871726.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):115-7 [18026687.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):133-40 [1309301.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1354-60 [9351573.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):756-62; discussion 762-3 [11322435.001]
  • [Cites] Acta Neuropathol. 1977 Jul 15;39(1):69-74 [899733.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Sep;13(9):1399-402 [3305450.001]
  • [Cites] Am J Surg Pathol. 1989 Apr;13(4):251-61 [2648875.001]
  • [Cites] Zentralbl Neurochir. 1986;47(3):191-9 [3811682.001]
  • [Cites] Am J Surg Pathol. 1982 Sep;6(6):573-80 [7149095.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):432-9 [12683870.001]
  • [Cites] Surg Neurol. 1985 Mar;23 (3):227-36 [3975803.001]
  • (PMID = 20198500.001).
  • [ISSN] 1590-3478
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


5. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature.
  • In extremely rare condition, meningioma may occur together with meningioangiomatosis, and only 19 cases have been described in English literature until now.
  • We now report a case of meningioangiomatosis-associated meningioma with atypical and clear cell variant.
  • Microscopically, parts of lesions were atypical and clear cell meningioma corresponding to WHO grade II.
  • Neoplastic cells in atypical meningioma area were immunoreactive to epithelial membrane antigen (EMA) with high MIB-1 index of up to 20%.
  • The diagnosis of atypical meningioma associated with sporadic meningioangiomatosis was made.
  • To our knowledge, this is the first case of a meningioangiomatosis-associated meningioma with atypical and clear cell variant component to be described.
  • Meningioangiomatosis-associated meningioma is more likely to occur in younger patients and histologically to mimic parenchymal invasion of brain.
  • We suggest that postoperative radiotherapy or chemotherapy should be given careful consideration to avoid over-treatment due to erroneously interpret as malignant meningioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


6. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathodiagnostic parameters for meningioma grading.
  • In this study the relationship between pathodiagnostic parameters, histological grade, and MIB-1 monoclonal antibody expression in meningioma diagnosed over 10 years in Shohada Hospital, Tehran, was assessed.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • Histopathological study of completely resected meningiomas showed that loss of architecture, frequent mitotic figures, a high cellularity, increased nucleo-cytoplasmic ratio, a prominent nucleolus, brain invasion, and necrosis were correlated with the grade of the meningiomas.
  • Overall, the mitotic count was the most important marker for tumor grade.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Iran. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Ubiquitin-Protein Ligases / metabolism. X-Ray Microtomography. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


7. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T: Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev; 2006 Oct;29(4):293-6; discussion 296-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and radiological features related to the growth potential of meningioma.
  • Clinical and radiological features that help predict the growth potential of meningioma would be beneficial.
  • We analyzed the relationship of MIB-1 staining indices to characteristics of 342 consecutive patients with meningioma surgically removed between 1995 and 2004 by logistic regression analysis.
  • One hundred and forty-nine of the patients with meningioma were >or=60 in age; 89 male; 48 recurrent; 203 symptomatic; 157 at the skull base; 124 over 20 cm(3); 24 multiple; 136 with edema; 117 with calcification.
  • The MIB-1 staining index in 56 of 296 grade I meningiomas in WHO classification was >or= 3.0; in 27 of 28 grade II; and in 17 of 18 grade III, respectively.
  • [MeSH-major] Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Coloring Agents. Female. Humans. Ki-67 Antigen. Logistic Models. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Odds Ratio. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Jan;68(1):25-8 [10601396.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):507-11 [10898357.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] Neurosurg Rev. 2003 Jul;26(3):221-8 [12690530.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):209-14 [15072469.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Surg Neurol. 1985 Aug;24(2):165-72 [4012573.001]
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):222-4 [7616265.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1049-55 [8584144.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):133-43 [8646709.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(1):26-31; discussion 31-2 [9522904.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] In Vivo. 2004 Jul-Aug;18(4):411-6 [15369177.001]
  • (PMID = 16953450.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC1564192
  •  go-up   go-down


8. Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, Lee MC, Lee DS: 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging; 2009 Oct;36(10):1574-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma.
  • PURPOSE: The purpose of this study was to investigate the role of (18)F-fluorodeoxyglucose (FDG) PET in detecting high-grade meningioma and predicting the recurrence in patients with meningioma after surgical resection.
  • METHODS: Fifty-nine patients (27 men and 32 women) with intracranial meningioma who underwent preoperative FDG PET and subsequent surgical resection were enrolled.
  • The tumor to gray matter ratio (TGR) of FDG uptake was calculated and a receiver-operating characteristic (ROC) curve of the TGR was drawn to determine the cutoff value of the TGR for detection of high-grade meningioma.
  • Further, univariate analysis with the log-rank test was performed to assess the predictive factors of meningioma recurrence.
  • RESULTS: The TGR in high-grade meningioma (WHO grade II and III) was significantly higher than that in low-grade ones (WHO grade I) (p=0.002) and significantly correlated with the MIB-1 labeling index (r=0.338, p=0.009) and mitotic count of the tumor (r=0.284, p=0.03).
  • The ROC analysis revealed that the TGR of 1.0 was the best cutoff value for detecting high-grade meningioma with a sensitivity of 43%, specificity of 95%, and accuracy of 81%.
  • In the log-rank test, the TGR, MIB-1 labeling index, presence of brain invasion, and WHO grade were significantly associated with tumor recurrence.
  • The cumulative recurrence-free survival rate of patients with a TGR of 1.0 or less was significantly higher than that of patients with a TGR of more than 1.0 (p=0.0003) CONCLUSION: FDG uptake in meningioma was the significant predictive factor of tumor recurrence and significantly correlated with the proliferative potential of the tumor.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Meningioma / diagnostic imaging. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Fluorine Radioisotopes. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnostic imaging. Positron-Emission Tomography. ROC Curve

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2004 Feb;61(2):149-55; discussion 155-6 [14751627.001]
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):339-44 [16765533.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Radiology. 2004 May;231(2):305-32 [15044750.001]
  • [Cites] Radiol Clin North Am. 2005 Jan;43(1):35-47 [15693646.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):542-9 [10853810.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1136-43 [15718309.001]
  • [Cites] J Neurosurg. 1998 May;88(5):831-9 [9576250.001]
  • [Cites] Radiology. 1995 Apr;195(1):47-52 [7892494.001]
  • [Cites] Int J Oncol. 2001 Jul;19(1):53-8 [11408922.001]
  • [Cites] Cancer. 1994 May 1;73(9):2386-94 [8168042.001]
  • [Cites] Eur J Nucl Med. 2000 Dec;27(12 ):1793-9 [11189942.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Mol Imaging Biol. 2008 Jan-Feb;10(1):1-18 [17957408.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):26-30 [8998144.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] J Neurosurg Sci. 1985 Jan-Mar;29(1):11-7 [4067631.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1074-8 [3261622.001]
  • (PMID = 19377904.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Bollag RJ, Vender JR, Sharma S: Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence. Neuropathology; 2010 Jun;30(3):279-87
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.
  • The current WHO 2007 classification divides meningiomas into a 3-grade prognostic hierarchy.
  • Recent literature evokes two pathways to disease progression in meningiomas akin to a comparable paradigm in gliomas, but without similar prognostic connotation: de novo anaplastic meningioma (better prognosis), and transformed meningioma (worse prognosis).
  • We present two adult cases of transformed meningiomas that display a spectrum of morphologic progression.
  • Case 1 at presentation showed a random admixture of meningothelial, atypical and anaplastic meningioma.
  • The tumor recurred as anaplastic meningioma.
  • Case 2 presented as a chordoid meningioma, but recurred as anaplastic meningioma mainly at the invasive front in transition with residual chordoid pattern.
  • In accordance with the dire prognosis for anaplastic meningioma, both patients succumbed to their disease within 2 months of recurrence.
  • The present study highlights two main points: First, that proper recognition of focal high-grade areas in a heterogeneous low-grade meningioma (case 1) provides critical morphologic clues to spatial histologic progression and predicts aggressive biologic behavior, as evidenced by progression to frankly anaplastic meningioma at recurrence.
  • Second, the presence of papillary in addition to anaplastic areas, in the recurrence of a previously diagnosed chordoid meningioma supports the ostensibly heightened transforming potential of grade II meningiomas, but also reflects on the morphologic heterogeneity of high-grade meningiomas, and their potentially diverse pathways of progression.
  • Future molecular genetic correlates, akin to those characterized in gliomas, could help stratify prognostic subcategories to refine meningioma grading, and govern optimal therapeutic strategies.
  • [MeSH-major] Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / pathology. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780983.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


10. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol; 2006 Jul;78(3):271-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent meningioma.
  • BACKGROUND: A prospective Phase II study of irinotecan (CPT-11) in adult patients with recurrent surgery and radiotherapy-refractory WHO Grade I meningioma.
  • METHODS: Sixteen patients (5 men; 11 women) ages 48-70 years (median 62.5), with recurrent meningioma were treated.
  • CPT-11 related-toxicity (> or = grade 3) included diarrhea (6 occurrences, 19% all cycles administered), granulocytopenia (6, 19%), leukopenia (5, 16%), thrombocytopenia (3, 10%) and anemia (3, 10%).
  • Using CPT-11 in this moderately toxic dose schedule failed to demonstrate efficacy in this cohort of adult patients with recurrent surgery and radiotherapy-refractory meningioma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jun;55(6):486-90 [1619417.001]
  • [Cites] J Neurooncol. 1990 Feb;8(1):61-5 [2319292.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):42-9 [10413154.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):269-72 [8858533.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):545-7 [2398385.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):65-72 [12134934.001]
  • [Cites] Neurology. 1997 May;48(5):1459-62 [9153494.001]
  • [Cites] Neurology. 1998 Dec;51(6):1718-20 [9855530.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Lancet. 1995 Feb 4;345(8945):331 [7837901.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):187-90 [8283254.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):552-9 [2002367.001]
  • (PMID = 16628476.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 0H43101T0J / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC: Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol; 2008 Mar;87(1):43-50
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue.
  • The fluorescence in situ hybridization (FISH) technique was used in 111 WHO grades I and II meningioma patients.
  • Significant differences for MIB-1 labeling were found between grades I and II tumors (p < 0.001), and between grade I tumors that recurred and those that did not recur (p < 0.001).
  • Chromosomal aberrations were detected with FISH analysis in nearly 50% of grade I, and in 93% of grade II meningiomas.
  • The findings suggest that adding FISH analysis may allow better prediction of possible meningioma recurrence and may be a useful adjunct for therapy decisions.
  • [MeSH-major] Chromosome Aberrations. In Situ Hybridization, Fluorescence. Ki-67 Antigen / metabolism. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2005 May;12(3):144-8 [15900115.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):666-75 [7931612.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] Neurosurgery. 2007 Nov;61(5):1048-59; discussion 1060-1 [18091281.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):241-6 [9258816.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5995-8 [10606247.001]
  • [Cites] Teratog Carcinog Mutagen. 2002;22(3):217-25 [11948632.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):333-40 [9689324.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Ann Genet. 1998;41(3):164-75 [9833072.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] Neurosurgery. 1995 Sep;37(3):478-82; discussion 483 [7501113.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):377-85 [11466693.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Curr Opin Neurol. 1993 Dec;6(6):882-7 [8293162.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1420-7 [9865827.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):878-84; discussion 884-5 [9316050.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Neuro Oncol. 2004 Oct;6(4):290-9 [15494096.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):99-108 [10982150.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(12):1231-8 [9932122.001]
  • (PMID = 18060363.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


12. Lakhdar F, Arkha Y, El Ouahabi A, Melhaoui A, Rifi L, Derraz S, El Khamlichi A: Intracranial meningioma in children: different from adult forms? A series of 21 cases. Neurochirurgie; 2010 Aug;56(4):309-14
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma in children: different from adult forms? A series of 21 cases.
  • The goal of this study of pediatric meningiomas was to establish their epidemiological profile as well as their clinical and radiological features, to assess the long-term outcome, and compare this result with adult meningioma.
  • PATIENT AND METHODS: We conducted a retrospective study from June 1983 to June 2007; during this period 521 patients underwent surgery for primary meningioma at the Rabat Hospital, Department of Neurosurgery.
  • Surgery achieved a Simpson grade I resection in 47%; 62% of the tumors were grade I and 24% were grade II based on World Health Organization pathological classification.
  • CONCLUSION: Pediatric meningiomas are larger than those found in the adult population; there is a male predominance with high incidence of a cystic component and high-grade meningiomas, thus explaining the increased recurrence rate despite the multimodal treatment.
  • [MeSH-major] Aging / pathology. Meningioma / pathology. Supratentorial Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20615516.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


13. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S: Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol; 2010 Jul;98(3):367-72
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after stereotactic radiotherapy of intracranial meningioma.
  • The aim of this work is to evaluate patterns of failure in patients with recurrent meningioma after stereotactic radiotherapy.
  • Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated.
  • The histologic grade of the meningiomas was World Health Organization (WHO) grade I in 54.5%, WHO grade II in 27.3%, and WHO grade III in 9.1% of cases.
  • Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III).
  • In the WHO grade I group, three recurrences were central and nine were marginal, whereas in the WHO grade II/III group seven recurrences were central and one was marginal.
  • Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma.
  • Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Retrospective Studies. Treatment Failure. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):362-72 [12527049.001]
  • [Cites] Neurosurg Rev. 2008 Oct;31(4):421-30; discussion 430 [18521636.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] J Neurosurg. 1999 May;90(5):823-7 [10223446.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Aug;67(2):153-71 [18342535.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] Cancer Radiother. 1999 Jul-Aug;3(4):311-7 [10486542.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):238-44; discussion 245-7 [9007855.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1147-55 [8083085.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1407-16 [19319527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1315-24 [10613328.001]
  • [Cites] Methods Enzymol. 2007;435:297-321 [17998060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16 [15708260.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Zentralbl Neurochir. 2008 Feb;69(1):14-21 [18393160.001]
  • [Cites] Radiologe. 1998 Mar;38(3):228-34 [9577869.001]
  • (PMID = 20012910.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Tena-Suck ML, Collado-Ortìz MA, Salinas-Lara C, García-López R, Gelista N, Rembao-Bojorquez D: Chordoid meningioma: a report of ten cases. J Neurooncol; 2010 Aug;99(1):41-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoid meningioma: a report of ten cases.
  • Chordoid meningioma is a rare variant of meningioma with histological features resembling those of chordoma.
  • This tumor has a great risk of recurrence and aggressive growth (WHO grade II).
  • This study was done to document the clinical and pathological features of ten patients with chordoid meningioma who submitted to surgery at the National Institute of Neurology and Neurosurgery in Mexico City.
  • Chordoid meningioma, World Health Organization grade II, is an uncommon variant of meningioma with a propensity for aggressive behavior and increased likelihood of recurrence.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Cell Adhesion Molecules / metabolism. Epithelial Cell Adhesion Molecule. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Retrospective Studies. S100 Proteins / metabolism. Vimentin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - TEN.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2006 Jul;78(3):263-9 [16628477.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1024-8 [16837627.001]
  • [Cites] Acta Cytol. 2009 May-Jun;53(3):297-302 [19534270.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2007 May-Jun;23(3):246-8 [17519674.001]
  • [Cites] Ultrastruct Pathol. 2006 Jul-Aug;30(4):309-14 [16971356.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Folia Neuropathol. 2006;44(1):34-41 [16565929.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):733-7 [15871519.001]
  • [Cites] Int Ophthalmol. 2008 Oct;28(5):355-7 [17898939.001]
  • [Cites] Ann Diagn Pathol. 2007 Jun;11(3):182-9 [17498592.001]
  • [Cites] Clin Neuropathol. 2004 Sep-Oct;23(5):232-7 [15581026.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Neurol Med Chir (Tokyo). 2006 Jan;46(1):37-40 [16434825.001]
  • [Cites] J Neurooncol. 2008 May;88(1):115-20 [18320142.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Mar;17(2):131-8 [19521276.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] Endocr Pathol. 2005 Fall;16(3):219-28 [16299405.001]
  • [Cites] Brain Pathol. 2006 Jan;16(1):15-9 [16612978.001]
  • [Cites] J Clin Neurosci. 2009 Mar;16(3):441-3 [19153045.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):899-905 [10895812.001]
  • [Cites] Neuropathology. 2006 Oct;26(5):438-41 [17080722.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):259-63 [15085764.001]
  • [Cites] Brain Tumor Pathol. 2008;25(2):91-5 [18987835.001]
  • [Cites] Acta Cytol. 2006 Nov-Dec;50(6):691-6 [17152286.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):669-81 [19194275.001]
  • [Cites] Acta Cytol. 2004 May-Jun;48(3):397-401 [15192958.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):391-406 [3383139.001]
  • [Cites] Childs Nerv Syst. 2006 Oct;22(10):1344-50 [16607533.001]
  • (PMID = 20094774.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


15. Li Y, Shi JT, An YZ, Zhang TM, Fu JD, Zhang JL, Zhao JZ: Sphenoid wing meningioma en plaque: report of 37 cases. Chin Med J (Engl); 2009 Oct 20;122(20):2423-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphenoid wing meningioma en plaque: report of 37 cases.
  • BACKGROUND: Sphenoid wing meningioma en plaque is a special morphological subgroup of intracranial meningiomas, defined by a carpet-like, soft tissue component that infiltrates the dura and invades the sphenoid wing and orbit associated with a significant hyperostosis.
  • This report summarized our experiences in 37 patients with sphenoid wing meningioma en plaque who had been treated with transcranio-orbital approach surgery.
  • RESULTS: Simpson grade II resection was achieved in 9 patients, Simpson grade III in 22 patients and Simpson grade IV in 6 patients.
  • CONCLUSIONS: Sphenoid wing meningioma en plaque, mainly meningothelial meningiomas, are more likely to produce adjacent hyperostosis and have characteristic radiological appearances.
  • [MeSH-major] Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079153.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Shimada S, Ishizawa K, Hirose T: Expression of E-cadherin and catenins in meningioma: ubiquitous expression and its irrelevance to malignancy. Pathol Int; 2005 Jan;55(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of E-cadherin and catenins in meningioma: ubiquitous expression and its irrelevance to malignancy.
  • According to the provided World Health Organization (WHO) grading, 84, 18 and five cases were classified as grade I, II and III, respectively.
  • Even in meningiomas of more than grade II, the expressions of cell adhesion molecules were detected in all cases.
  • The present study demonstrates that cell adhesion molecules are ubiquitously expressed in all variants of meningioma and may be involved in the tumor morphogenesis.
  • The present study also suggests that these markers may be useful for the differential diagnosis of meningioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cadherins / biosynthesis. Cytoskeletal Proteins / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Hemangioblastoma / metabolism. Hemangioblastoma / pathology. Hemangiopericytoma / metabolism. Hemangiopericytoma / pathology. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660696.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cytoskeletal Proteins
  •  go-up   go-down


17. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A: Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology; 2007 Apr;27(2):114-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
  • Although most are benign, between 5% and 15% of meningiomas are atypical (grade II) whereas 1-2% are anaplastic meningiomas (grade III).
  • Although histological grade is the most relevant prognostic factor, there are some unusual cases in which establishing a diagnosis of high-grade meningioma following 2000 World Health Organization (WHO) histological criteria is extremely difficult.
  • Therefore, the aim of the present study was to evaluate the predictive value of Ki-67 labeling index and its contribution to current WHO classification in predicting tumor recurrence and overall survival in patients with high-grade meningiomas.
  • Median Ki-67 labeling index in the whole series was 7.0 (0.5-31.5) with no differences with respect to the histological grade (P = 0.87).
  • More importantly, this predictive value was maintained in both patients with atypical and patients with anaplastic meningioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neuropathology. 2008 Feb;28(1):106-7 [18181839.001]
  • (PMID = 17494511.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


18. Ghosal N, Furtado SV, Santosh V, Sridhar M, Hegde AS: Co-existing fibrous dysplasia and atypical lymphoplasmacyte-rich meningioma. Neuropathology; 2007 Jun;27(3):269-72
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-existing fibrous dysplasia and atypical lymphoplasmacyte-rich meningioma.
  • We report an unusual and extremely rare case of coexisting fibrous dysplasia of the sphenoid sinus with atypical lymphoplasmacyte rich meningioma (World Health Organization Grade II), right frontal lobe in a 25-year-old male.
  • [MeSH-major] Fibrous Dysplasia, Monostotic / complications. Fibrous Dysplasia, Monostotic / pathology. Meningeal Neoplasms / complications. Meningeal Neoplasms / pathology. Meningioma / complications. Meningioma / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Sphenoid Bone / pathology. Sphenoid Sinus / pathology

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645241.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


19. Bacciu A, Piazza P, Di Lella F, Sanna M: Intracanalicular meningioma: clinical features, radiologic findings, and surgical management. Otol Neurotol; 2007 Apr;28(3):391-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracanalicular meningioma: clinical features, radiologic findings, and surgical management.
  • PATIENTS: Thirteen consecutive patients with pathologically confirmed intracanalicular meningioma surgically treated between December 1988 and July 2006.
  • The postoperative facial nerve function was either excellent or good (House-Brackmann Grade I or II) in 10 cases (77%) and acceptable (Grade III) in one case.
  • On account of a lack of specific symptoms and the limited diagnostic findings, preoperative diagnosis of intracanalicular meningioma still represents a diagnostic challenge.
  • [MeSH-major] Ear Neoplasms / pathology. Ear Neoplasms / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Otologic Surgical Procedures / methods. Vestibular Aqueduct / pathology. Vestibular Aqueduct / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Audiometry, Pure-Tone. Evoked Potentials, Auditory, Brain Stem. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287658.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Sanai N, Sughrue ME, Shangari G, Chung K, Berger MS, McDermott MW: Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg; 2010 May;112(5):913-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk profile associated with convexity meningioma resection in the modern neurosurgical era.
  • RESULTS: Between 1997 and 2007, 141 consecutive patients (median age 48 years, range 18-95 years) underwent resection of a supratentorial convexity meningioma.
  • A Simpson Grade 0 or 1 resection was achieved in 122 patients (87%).
  • One hundred six tumors (75%) were WHO Grade I, whereas 35 (25%) were WHO Grade II.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Neurosurgical Procedures / methods. Radiosurgery / methods. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Complications / epidemiology. Intraoperative Complications / prevention & control. Male. Microsurgery / instrumentation. Middle Aged. Risk Assessment. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645533.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kozler P, Benes V, Netuka D, Kramár F, Hrabal P, Charvát F: Chordoid meningioma: presentation of two case reports, review of the literature, and plea for data standardisation. J Neurooncol; 2008 May;88(1):115-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoid meningioma: presentation of two case reports, review of the literature, and plea for data standardisation.
  • Chordoid meningioma is a rare variant of meningioma with histological features resembling those of chordoma.
  • This tumour should have a greater risk of recurrence and aggressive growth (WHO grade II).
  • We report two cases of chordoid meningioma occurring in adult female patients.
  • In our two patients (aged 28 and 60 years with chordoid meningioma of the convexity and left-sided outer sphenoid wing, respectively) we centred on some rarely discussed aspects of the tumour.
  • In both cases, the tumour was removed by radical surgery (Simpson grade I resection) with a normal post-operative course.
  • We regard the factors under consideration in our study (i.e. absence of edema, dural supply, low VEGF expression and radical Simpson grade I resection) as an important contribution to the discussion of the biological behaviour of chordoid meningioma.
  • [MeSH-major] Meningioma / pathology
  • [MeSH-minor] Adult. Biopsy. Cerebrovascular Circulation. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures. Vimentin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chin Med J (Engl). 2007 Apr 20;120(8):726-8 [17517194.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):263-9 [16628477.001]
  • [Cites] Neurochirurgie. 2007 Feb;53(1):39-42 [17337015.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1024-8 [16837627.001]
  • [Cites] Bull Acad Natl Med. 2003;187(3):591-8; discussion 598-600 [14556472.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):476-80 [9526980.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2007 May-Jun;23(3):246-8 [17519674.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):397-401 [16792549.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurol Med Chir (Tokyo). 2006 Jan;46(1):37-40 [16434825.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):319-23 [9452243.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] J Neurosurg. 1997 Sep;87(3):368-73 [9285600.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):899-905 [10895812.001]
  • [Cites] Neuropathology. 2006 Oct;26(5):438-41 [17080722.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):732-40; discussion 740-1 [10201297.001]
  • [Cites] Acta Cytol. 2006 Nov-Dec;50(6):691-6 [17152286.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):109-20 [11245271.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):391-406 [3383139.001]
  • (PMID = 18320142.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  •  go-up   go-down


22. Marton E, Bonaldi L, Busato S, Longatti P: Atypical meningioma in Werner syndrome: a case report. J Neurooncol; 2006 Sep;79(2):181-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical meningioma in Werner syndrome: a case report.
  • INTRODUCTION: Werner Syndrome, or adult progeria, is a rare autosomal recessive disorder caused by a mutation in the Werner Syndrome Gene belonging to the family of RecQ helicase.
  • CLINICAL PRESENTATION: We present the case of a 46-year-old man with Werner Syndrome and a convexity meningioma.
  • He underwent surgery with Simpson grade II removal, with improvement of the slight paresis and no other neurological defects.
  • Histological examination revealed an atypical meningioma.
  • CONCLUSION: 1p deletion correlates with meningioma progression and in this case correlates with histological examination.
  • [MeSH-major] Brain Neoplasms / complications. Chromosomes, Human, Pair 22 / genetics. Meningioma / complications. Monosomy / diagnosis. Werner Syndrome / complications

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Werner's syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2004 May;54(5):1263-6; discussion 1266-7 [15113484.001]
  • [Cites] No To Shinkei. 1994 Nov;46(11):1069-74 [7873280.001]
  • [Cites] J Orthop Surg (Hong Kong). 2003 Dec;11(2):224-33 [14676353.001]
  • [Cites] Neurobiol Aging. 1996 May-Jun;17(3):325-30 [8725892.001]
  • [Cites] Nat Genet. 2004 Aug;36(8):877-82 [15235603.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):239-46 [8722214.001]
  • [Cites] J Clin Neurosci. 2005 May;12(4):503-6 [15925797.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] No Shinkei Geka. 1988 Feb;16(2):189-94 [3285233.001]
  • [Cites] Clin Genet. 1981 Jan;19(1):8-15 [7460386.001]
  • [Cites] Neurosurgery. 1980 Nov;7(5):517-20 [7003435.001]
  • [Cites] Br J Dermatol. 1997 Apr;136(4):620-3 [9155973.001]
  • [Cites] Dermatologica. 1989;178(2):118-20 [2924983.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):791-802 [12771022.001]
  • [Cites] Gerontology. 2002 Jul-Aug;48(4):215-9 [12053110.001]
  • (PMID = 16598422.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Baxter DS, Smith P, Stewart K, Murphy M: Clear cell meningioma presenting as rapidly deteriorating visual field and acuity during pregnancy. J Clin Neurosci; 2009 Nov;16(11):1502-4
MedlinePlus Health Information. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma presenting as rapidly deteriorating visual field and acuity during pregnancy.
  • Clear cell meningioma is a rare histological phenotype of meningioma.
  • It has an atypical grade II World Health Organization classification due to a high recurrence rate.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningioma / complications. Perceptual Disorders / etiology. Pregnancy / physiology. Visual Acuity / physiology. Visual Fields / physiology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632846.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


24. Ozen O, Demirhan B, Altinörs N: Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol; 2005 Sep-Oct;24(5):219-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
  • The aim of this study was to re-evaluate tumors diagnosed as meningioma previously in our hospital, according to the latest World Health Organization classification.
  • We also examined the relationships among parameters such as brain invasion, histological grade and Ki-67 and p53 expression in these tumors.
  • MATERIALS AND METHODS: Meningioma biopsy specimens numbering 60 (48 grade I, 11 grade II, and 1 grade III tumors) were examined immunohistochemically using monoclonal antibodies for Ki-67 (MIB-1) and p53 protein.
  • The mean MIB-1 LI values for the grade I and grade II tumors were 1.1% and 2.3%, respectively.
  • The MIB-1 LI and the level of p53 expression in the one grade III meningioma were 6.7% and 10 - 70%, respectively.
  • Histological grade was significantly correlated with MIB-1 LI and with p53 expression (p < 0.01 for both).
  • Brain invasion was not correlated with histological grade, MIB-1 LI, or p53 expression.
  • CONCLUSION: The results indicate that MIB-1 LI and p53 protein expression are good indicators of histological grade in meningioma and may be particularly valuable for distinguishing borderline atypical meningiomas.
  • The number of cases was limited, but the findings also suggest that brain invasion is a prognostic parameter independent of grade, MIB-1 LI and p53 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167545.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


25. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Aricò D, Sansovini M, Paganelli G: Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging; 2009 Sep;36(9):1407-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
  • However, for high-grade histotypes or partially resected tumours, recurrence is fairly common.
  • We assessed peptide receptor radionuclide therapy (PRRT) using (90)Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces.
  • METHODS: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease.
  • Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Octreotide / analogs & derivatives. Radiopharmaceuticals / therapeutic use. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Young Adult. Yttrium Radioisotopes

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):132-6 [16625862.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46 [15150675.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10):1599-606 [17015894.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):133-40 [11965608.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Mar;74(3):543-7 [1346787.001]
  • [Cites] Digestion. 1993;54 Suppl 1:76-83 [8103015.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Aug;63(2):433-8 [3013920.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Feb;19(1):65-71 [15068613.001]
  • [Cites] Surg Neurol. 1989 Apr;31(4):255-60 [2928917.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):107-13; discussion 107-13 [15987576.001]
  • [Cites] Biopolymers. 2002;66(6):393-8 [12658726.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Hereditas. 1972;71(1):163-8 [4142025.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):207-16 [12552338.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Acta Oncol. 2007;46(6):723-34 [17653893.001]
  • [Cites] J Nucl Med. 2006 Sep;47(9):1467-75 [16954555.001]
  • [Cites] Neurology. 2007 Sep 4;69(10):969-73 [17785665.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):163-73 [17219818.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 May;34(5):772-86 [17268773.001]
  • [Cites] Expert Rev Neurother. 2006 Oct;6(10):1447-64 [17078786.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51 [16847654.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] Semin Nucl Med. 2002 Apr;32(2):141-7 [11965609.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] Pediatr Neurosci. 1988;14(6):319-23 [3270054.001]
  • [Cites] Eur J Nucl Med. 2001 Apr;28(4):426-34 [11357492.001]
  • [Cites] J Nucl Med. 2005 May;46(5):763-9 [15872348.001]
  • [Cites] Am J Clin Oncol. 1986 Aug;9(4):337-40 [3751972.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Can J Neurol Sci. 1997 Nov;24(4):302-6 [9398976.001]
  • [Cites] Humangenetik. 1972;14(2):167-9 [4112733.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1913-7 [9829583.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • (PMID = 19319527.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 0 / Yttrium Radioisotopes; 0 / somatostatin receptor 2; RWM8CCW8GP / Octreotide; U194AS08HZ / Edotreotide
  •  go-up   go-down


26. Erman T, Hanta I, Haciyakupoğlu S, Zorludemir S, Zeren H, Göçer AI: Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature. J Neurooncol; 2005 Sep;74(2):179-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature.
  • A case of recurrent meningioma with atypical features and extracranial metastases is reported.
  • A 34-year-old female was operated in 1996, 2000, and 2002, and frontal parasagittal meningioma was extirpated.
  • Histological diagnoses of all the resected tumors were meningotheliomatous meningioma, WHO Grade I.
  • Histological diagnosis was reported as an atypical meningioma; meningotheliomatous type; WHO Grade II.
  • Cytopathology was consistent with malignant meningioma, metastasis from the patient's known intracranial meningioma.
  • We reviewed and discussed the histopathological features and mechanisms of metastasizing meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 1995 Aug;45(8):617-21 [7496509.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8 [8955436.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Diagn Cytopathol. 1999 May;20(5):291-4 [10319230.001]
  • [Cites] J Clin Neurosci. 2000 Jan;7(1):69-72 [10847658.001]
  • [Cites] Br J Radiol. 1999 May;72(857):513-6 [10505022.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1144-50 [8214259.001]
  • [Cites] Acta Neurol Scand. 2000 Sep;102(3):200-2 [10987382.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Clin Nucl Med. 2002 Oct;27(10 ):701-4 [12352110.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Mayo Clin Proc. 1999 Nov;74(11):1129-33 [10560602.001]
  • [Cites] Surg Today. 1998;28(9):953-8 [9744408.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Mar;21(3):553-5 [11888783.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 16193389.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Jager B, Schuhmann MU, Schober R, Kortmann RD, Meixensberger J: Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood. Pediatr Neurosurg; 2008;44(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood.
  • A local recurrence, grade WHO III, with signs of focal sarcomatous transformation, was subtotally resected 13 years later in 2001.
  • A new and fast growing right frontal meningioma, grade WHO II, was removed in 2003.
  • Irradiation-induced meningiomas in children are known to occur, however not following radiotherapy of low-grade hemispheric gliomas.
  • [MeSH-major] Astrocytoma / radiotherapy. Gliosarcoma / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Adult. Humans. Male. Radiotherapy / adverse effects


28. Hernández Faraco A, Céspedes G, Trejo E: [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. Neurologia; 2009 May;24(4):235-44
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas].
  • The histological grade of the WHO and the extension of the initial surgical resection are determining prognostic factors in these tumors.
  • METHODS: A total of 93 cases were selected for the immunohistochemical study of the progesterone receptor (PR) in relation to the histological grade and the risk of recurrencies in meningiomas.
  • RESULTS: Though the immunohistochemical labelling index (LI) of the PR decreased with the progression of the histological grade (means of 27.37 % for grade I, 17.89% for grade II, and 13.50% for grade III), such correlation was not statistically significant and the cut off estimated in 20% was not satisfactory to discriminate among benign meningiomas (grade I) and non benign (grades II-III) due to its poor sensitivity (56.10%) and positive predictive value (56.10 %).
  • CONCLUSION: The LI of the PR is apparently not related to the histological grade of the meningiomas, but is significantly smaller in recurrent meningiomas.
  • A meningioma with a LI of the PR less than 40 % suggests the risk of recurrences.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Receptors, Progesterone / biosynthesis
  • [MeSH-minor] Adult. Biomarkers, Tumor. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Risk Assessment. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19603293.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone
  •  go-up   go-down


29. Tong-tong W, Li-juan B, Zhi L, Yang L, Bo-ning L, Quan H: Clear cell meningioma with anaplastic features: case report and review of literature. Pathol Res Pract; 2010 May 15;206(5):349-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma with anaplastic features: case report and review of literature.
  • Clear cell meningioma (CCM) is an uncommon variant of meningioma, corresponding to WHO grade II.
  • A diagnosis of CCM with anaplastic features was made (WHO grade III).
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Anaplasia / pathology. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19857933.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Smith JS, Quiñones-Hinojosa A, Harmon-Smith M, Bollen AW, McDermott MW: Sex steroid and growth factor profile of a meningioma associated with pregnancy. Can J Neurol Sci; 2005 Feb;32(1):122-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex steroid and growth factor profile of a meningioma associated with pregnancy.
  • METHODS: We describe the presentation of a meningioma during the immediate postpartum period.
  • RESULTS: The lesion proved to be an atypical fibroblastic meningioma grade II (WHO).
  • CONCLUSION: Although clinical regression of meningioma following pregnancy is well-recognized, imaging data are much less abundant.
  • This report provides clear clinical and imaging documentation of a meningioma associated with pregnancy.
  • [MeSH-major] Growth Substances / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology. Pregnancy Complications. Receptors, Steroid / metabolism
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Placental Lactogen / metabolism. Postpartum Period. Pregnancy. Proto-Oncogene Proteins c-sis / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, Fibroblast Growth Factor, Type 2. Receptors, Estrogen / metabolism. Receptors, Fibroblast Growth Factor / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825560.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, Estrogen; 0 / Receptors, Fibroblast Growth Factor; 0 / Receptors, Progesterone; 0 / Receptors, Steroid; 9035-54-5 / Placental Lactogen; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2
  •  go-up   go-down


31. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J: WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol; 2009 Dec;95(3):367-375
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WHO grade II and III meningiomas: a study of prognostic factors.
  • Grades II and III meningiomas have been less well studied and are not well controlled because of their aggressive behaviour and recurrences.
  • This study was performed on 199 adults treated for WHO grade II (166 patients) or grade III (33 patients) meningiomas between 1990 and 2004 in the Neurosurgery Departments of five French University Hospitals.
  • For patients with grade II meningiomas, the 5- and 10-year OS rates were 78.4 and 53.3%, respectively, while, for patients with grade III meningiomas, the corresponding values were 44.0 and 14.2%.
  • For patients with grade II meningiomas, the 5- and 10-year PFS rates were 48.4 and 22.6%, respectively, the corresponding values for patients with grade III meningiomas being 8.4 and 0%.
  • For the grade II meningiomas, univariate analysis showed that age < 60 years (P < 0.0001) and Simpson 1 resection (P = 0.055) were associated with a longer OS.
  • For the grade III meningiomas, univariate analysis showed that age < 60 years (P < 0.0001) and RT (P = 0.036) were associated with a longer OS.
  • Histological grade II was found to be associated with a longer PFS (P = 0.0032) and RT reduced the PFS in grade II meningiomas (P = 0.0006) There were no other prognostic factors in terms of PFS for grades II and III meningiomas in univariate analysis.
  • Multivariate analysis confirmed that age (< 60 years), Simpson 1 and histological grade II were independent prognostic factors for survival.
  • This retrospective study might improve the management of grades II and III meningiomas.
  • Prospective trials should delineate strong therapeutic guidelines for high-grade meningiomas.
  • [MeSH-major] Meningeal Neoplasms / mortality. Meningeal Neoplasms / pathology. Meningioma / mortality. Meningioma / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Cause of Death. Databases, Factual. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Rev. 2003 Jul;26(3):221-8 [12690530.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] Hum Mutat. 2006 Apr;27(4):297-306 [16521120.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Br J Neurosurg. 2008 Aug;22(4):520-8 [18803079.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):177-88 [9524097.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):1-6 [19023520.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1388-93 [18294779.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1102-10 [10964341.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Neurosurg Focus. 1997 Apr 15;2(4):e3 [15096007.001]
  • [Cites] Neuropathology. 2007 Apr;27(2):114-20 [17494511.001]
  • (PMID = 19562258.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D: The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol; 2005 Apr;31(2):141-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of meningioma grading: a 10-year retrospective audit.
  • Although descriptive classifications of meningioma subtypes are well established, there has been inconsistency in the categorization of meningiomas into benign, atypical and anaplastic groups.
  • The aim of this study was to reassess the incidence of atypical (grade II) meningiomas over a 10-year period by applying the World Health Organization (WHO) 2000 classification system.
  • A secondary aim was to determine if grade II and III tumours were becoming more common.
  • On reclassification, 78% of the meningiomas were classified as grade I, 20.4% as grade II and 1.6% as grade III.
  • With regard to grade II meningiomas classified by using the WHO 2000 classification system, 38.1% had originally been classified as grade I prior to 2000, whereas 13.6% had originally been classified as grade I after 2000.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningeal Neoplasms / pathology. Meningioma / classification. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771707.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Lin JW, Ho JT, Lin YJ, Wu YT: Chordoid meningioma: a clinicopathologic study of 11 cases at a single institution. J Neurooncol; 2010 Dec;100(3):465-73
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoid meningioma: a clinicopathologic study of 11 cases at a single institution.
  • Chordoid meningioma is an uncommon variant of meningioma, which histologically bears a great resemblance to chordoma and often follows an aggressive clinical course.
  • Thirteen specimens of chordoid meningioma belonging to 11 patients were obtained at a single institution from 1995 to 2009.
  • Six tumors (46%) were classified as benign (grade I) and seven tumors (54%) atypical (grade II), if based solely on histologic grading irrespective of chordoid or clear cell components in our cases.
  • [MeSH-major] Choroid Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Retrospective Studies. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2011 Aug;104(1):395-7 [21136280.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):263-9 [16628477.001]
  • [Cites] Acta Neuropathol. 2005 May;109(5):497-502 [15864611.001]
  • [Cites] Clin Neurol Neurosurg. 2008 Jul;110(7):743-6 [18514392.001]
  • [Cites] Eur J Histochem. 1995;39(1):21-30 [7612954.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):122-6 [11147880.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1490-7 [15990898.001]
  • [Cites] J Neurosurg Spine. 2005 Feb;2(2):195-8 [15739533.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):397-401 [16792549.001]
  • [Cites] Ultrastruct Pathol. 2006 Jul-Aug;30(4):309-14 [16971356.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):493-9 [16411134.001]
  • [Cites] Clin Neuropathol. 2004 Nov-Dec;23(6):277-85 [15584212.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Mar;61(1):91-4 [12715027.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):555-8 [16235690.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):733-7 [15871519.001]
  • [Cites] Int Ophthalmol. 2008 Oct;28(5):355-7 [17898939.001]
  • [Cites] J Neurosurg Pediatr. 2008 Oct;2(4):269-72 [18831662.001]
  • [Cites] Acta Neuropathol. 1989;79(2):211-6 [2596270.001]
  • [Cites] Brain Tumor Pathol. 2000;17 (3):153-7 [11310923.001]
  • [Cites] Brain Tumor Pathol. 2009;26(1):37-42 [19408096.001]
  • [Cites] Neurol India. 2003 Dec;51(4):522-4 [14742937.001]
  • [Cites] J Neurooncol. 1994;18(3):199-206 [7525890.001]
  • [Cites] Adv Anat Pathol. 2006 Mar;13(2):83-8 [16670463.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):319-23 [9452243.001]
  • [Cites] J Neurooncol. 2008 May;88(1):115-20 [18320142.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):445-447 [19557500.001]
  • [Cites] Pathol Res Pract. 2001;197(7):515-8; discussion 519 [11482583.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5291-5 [3523489.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):899-905 [10895812.001]
  • [Cites] Acta Neuropathol. 2007 Jan;113(1):87-94 [17021752.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5):E1064; discussion E1064 [16284544.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):669-81 [19194275.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):243-7 [15484703.001]
  • [Cites] Am J Pathol. 1997 Oct;151(4):1141-52 [9327748.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):391-406 [3383139.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • (PMID = 20454999.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Ki-67 Antigen; 0 / Mucin-1
  •  go-up   go-down


34. Cramer P, Thomale UW, Okuducu AF, Lemke AJ, Stockhammer F, Woiciechowsky C: An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report. J Neurosurg Spine; 2005 Aug;3(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
  • Following intraspinal decompression the tumor was histologically classified as an atypical meningioma (World Health Organization grade II).
  • Two further surgical interventions resulted in almost total removal of the meningioma.
  • The results in the reported case indicate that meningiomas associated with cerebrospinal fluid metastasis may represent a higher grade of malignancy.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cervical Vertebrae. Decompression, Surgical. Disease Progression. Fatal Outcome. Humans. Hydroxyurea / therapeutic use. Joint Instability / etiology. Magnetic Resonance Imaging. Male. Myelography. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neurosurgical Procedures / adverse effects. Radiotherapy, Adjuvant. Reoperation. Spinal Diseases / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16370305.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


35. Liu RS, Chang CP, Guo WY, Pan DH, Ho DM, Chang CW, Yang BH, Wu LC, Yeh SH: 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med; 2010 Jun;51(6):883-91
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery.
  • METHODS: Twenty-two patients with the neuroradiologic diagnosis of meningioma were examined by 1-(11)C-acetate and (18)F-FDG PET on the same day.
  • There were 12 cases of histopathologically proven meningioma (8 grade I, 2 grade II, and 2 grade III), 1 of tuberculous granuloma, and 1 of degenerative tissue.
  • RESULTS: The (18)F-FDG PET study revealed a hypometabolic focus in 17 meningiomas (8 grade I, 1 grade II, and 8 unknown grade) and hypermetabolism in 1 grade II and 2 grade III meningiomas.
  • The standardized uptake value for 1-(11)C-acetate was not different from that for (18)F-FDG (mean +/- SD, 3.16 +/- 1.75 vs. 3.22 +/- 1.50, P = 0.601), but the tumor-to-cortex ratio for 1-(11)C-acetate was higher than that for (18)F-FDG (3.46 +/- 1.38 vs. 0.93 +/- 1.08, P < 0.005). (18)F-FDG was able to differentiate grade I from grade II-III meningiomas, whereas 1-(11)C-acetate was unable to do so.
  • Tuberculous granuloma had a high 1-(11)C-acetate and (18)F-FDG uptake similar to that of grade II/III meningioma.
  • However, 1-(11)C-acetate was not useful for evaluating the tumor grade. (18)F-FDG was found to be less useful than 1-(11)C-acetate for evaluating the extent of meningiomas and the response to radiosurgical treatment but may be useful for differentiating benign from malignant meningiomas. (18)F-FDG and 1-(11)C-acetate are complementary for assessing diverse cell metabolism of meningioma.
  • [MeSH-major] Acetates. Carbon. Fluorodeoxyglucose F18. Meningioma / radionuclide imaging. Meningioma / surgery. Positron-Emission Tomography / methods. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biological Transport. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Regression Analysis. Retrospective Studies. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484430.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


36. Zhang MX, Zhao X, Wang ZG, Zhao WM, Wang YS: Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation. J Cancer Res Clin Oncol; 2010 Jul;136(7):981-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation.
  • The function of STAT3 in the pathogenesis of meningioma remains unknown.
  • In this study, we investigated the role of JAK1/STAT3 regulating vascular endothelial growth factor (VEGF) expression in the occurrence and progression of human meningioma.
  • METHODS: We detected the expression of JAK1, p-JAK1, STAT3, p-STAT3, and VEGF in human meningioma and normal dura tissues by RT-PCR, Western blot analysis, and immunohistochemistry.
  • RESULTS: JAK1, p-JAK1, STAT3, p-STAT3, and VEGF showed high expression in grade I and grade II meningioma.
  • The level of STAT3 activation was associated with VEGF expression; all meningioma tumors that expressed p-STAT3 also expressed VEGF.
  • Both frequency of positivity and expression were enhanced with increasing tumor grade; high frequencies and levels were found in grade II tumors, with no expression detected in normal dura tissues (P < 0.05).
  • CONCLUSIONS: VEGF is directly regulated by constitutive STAT3 activity and associated with meningioma differentiation.
  • STAT3 has an important role in the occurrence and development of human meningioma by regulating VEGF expression.
  • [MeSH-major] Janus Kinase 1 / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. STAT3 Transcription Factor / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Blotting, Western. Disease Progression. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Sep 15;84(6):1760-4 [7521688.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):153-9 [8380810.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):811-20 [8642285.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):21872-7 [9268319.001]
  • [Cites] Cell. 1998 May 1;93(3):373-83 [9590172.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2381-7 [9703883.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1411-6 [9816315.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Stem Cells. 1999;17(3):138-46 [10342556.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):440-6 [10470819.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1173-7 [16136500.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):171-9 [16846476.001]
  • [Cites] Brain Res. 2006 Jul 7;1098(1):26-32 [16764840.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):378-83 [17595657.001]
  • [Cites] Oncogene. 2008 Mar 6;27(11):1511-9 [17873904.001]
  • [Cites] Oncol Rep. 2008 Dec;20(6):1321-7 [19020709.001]
  • [Cites] Cancer Biol Ther. 2008 Dec;7(12):1994-2003 [18981713.001]
  • [Cites] PLoS One. 2009;4(5):e5578 [19440292.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Laryngoscope. 2000 May;110(5 Pt 1):868-74 [10807365.001]
  • [Cites] Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):439-46 [10817928.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24935-44 [10823829.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):327-34 [11310826.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6613-26 [11426647.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):536-42 [11740806.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2058-65 [11960378.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):319-29 [12545153.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3863-71 [14500688.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1421-9 [7537214.001]
  • (PMID = 20052595.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.010.2 / JAK1 protein, human; EC 2.7.10.2 / Janus Kinase 1
  • [Other-IDs] NLM/ PMC2874489
  •  go-up   go-down


37. Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Agúndez JA, García-Martín E: Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol; 2010;10:71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.
  • Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the putative association between common nonsynonymous PON1 polymorphisms and the risk of developing astrocytoma and meningioma.
  • METHODS: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662.
  • All participants were adult Caucasian individuals recruited in the central area of Spain.
  • RESULTS: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1 Q192R did not differ significantly between patients with astrocytoma and meningioma and controls.
  • The minor allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and control individuals, respectively.
  • Haplotype association analyses did not identify any significant association with the risk of developing astrocytoma or meningioma.
  • CONCLUSIONS: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing astrocytoma and meningioma.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single Nucleotide. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):341-9 [9712341.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 1;56(5):547-51 [9783722.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Liver Int. 2005 Oct;25(5):935-9 [16162149.001]
  • [Cites] Toxicology. 2005 Nov 15;215(3):182-90 [16102884.001]
  • [Cites] Occup Environ Med. 2005 Nov;62(11):786-92 [16234405.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):615-20 [16489678.001]
  • [Cites] Acta Neurol Scand. 2006 May;113(5):322-6 [16629768.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1513-6 [16685388.001]
  • [Cites] Pharmacogenomics. 2006 Jul;7(5):711-8 [16886896.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Drug Metab Dispos. 2007 Feb;35(2):315-20 [17132760.001]
  • [Cites] Occup Environ Med. 2007 Aug;64(8):509-14 [17537748.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jan;18(1):37-43 [18216720.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):976-85 [18299277.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1390-4 [18664443.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):520-31 [18680472.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Psychiatr Genet. 2008 Dec;18(6):289-94 [19018234.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):142-53 [19371602.001]
  • [Cites] Cell Biochem Funct. 2009 Dec;27(8):558-67 [19902425.001]
  • [Cites] Environ Health Perspect. 2010 Jan;118(1):144-9 [20056567.001]
  • [Cites] Adv Exp Med Biol. 2010;660:47-60 [20221870.001]
  • [Cites] Eur J Neurol. 2010 Jun 1;17(6):879-81 [20050883.001]
  • [Cites] Chem Biol Interact. 2010 Sep 6;187(1-3):355-61 [20338154.001]
  • [Cites] Neuromolecular Med. 2010 Sep;12(3):217-23 [19826962.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23 [10099836.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] J Lipid Res. 2001 Apr;42(4):528-35 [11290824.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6 [11350209.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Curr Opin Lipidol. 2002 Aug;13(4):357-62 [12151850.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):139-50 [12749719.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):182-4 [12820764.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Mol Med (Berl). 2003 Dec;81(12):766-79 [14551701.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Arch Pathol Lab Med. 1979 Dec;103(13):676-9 [583126.001]
  • [Cites] J Neurol. 1982;227(3):165-9 [6181224.001]
  • [Cites] Indian J Cancer. 1983 Mar;20(1A):86-8 [6873998.001]
  • [Cites] Am J Epidemiol. 1988 Oct;128(4):778-85 [3421243.001]
  • [Cites] Neurologia. 1988 Mar-Apr;3(2):68-70 [2856211.001]
  • [Cites] J Neurosci Nurs. 1992 Oct;24(5):260-4 [1328422.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):598-608 [7916578.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):73-6 [8098250.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] J Neurosurg Sci. 1995 Mar;39(1):27-35 [8568553.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Curr Opin Lipidol. 1996 Apr;7(2):69-76 [8743898.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):334-6 [8896566.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):284-7 [9685159.001]
  • (PMID = 20723250.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  • [Other-IDs] NLM/ PMC2936881
  •  go-up   go-down


38. Barresi V, Alafaci C, Salpietro F, Tuccari G: Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep; 2008 Sep;20(3):485-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?
  • In the present study, sstr2A immunohistochemical expression was analyzed in grade II and III meningiomas and was compared with that revealed in grade I meningiomas.
  • Thirty-five formalin-fixed paraffin-embedded meningiomas, comprising 13 grade I, 19 grade II and 3 grade III tumours, according to the WHO 2007 classification, were submitted to immunohistochemical assays for sstr2A.
  • Specifically, a positive staining was found in 7/13 grade I, in 16/19 grade II and in 3/3 grade III tumours, thus demonstrating that sstr2A is frequently expressed in high grade meningiomas.
  • A significantly higher microvessel density (MVD), assessed by CD105 immunostaining and Ki-67 LI were evidenced in high grade meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Proliferation. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neovascularization, Pathologic / pathology. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Cell Surface / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695896.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Cell Surface; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2
  •  go-up   go-down


39. Nakaya K, Chernov M, Kasuya H, Izawa M, Hayashi M, Kato K, Kubo O, Muragaki Y, Iseki H, Hori T, Okada Y, Takakura K: Risk factors for regrowth of intracranial meningiomas after gamma knife radiosurgery: importance of the histopathological grade and MIB-1 index. Minim Invasive Neurosurg; 2009 Oct;52(5-6):216-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for regrowth of intracranial meningiomas after gamma knife radiosurgery: importance of the histopathological grade and MIB-1 index.
  • INTRODUCTION: The influence of histopathological grade and MIB-1 index of intracranial meningioma on the results of its radiosurgical management is not clear.
  • Tumors of WHO histopathological grades I, II, and III were diagnosed in 24, 3, and 7 cases, respectively.
  • Histopathological grade II or III (p<0.0001), MIB-1 index 3% and more (p=0.0004), and non-skull base location (p=0.0026) of the tumor showed negative associations with progression-free survival in multivariate analyses.
  • [MeSH-major] Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Radiosurgery
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Proliferation. Disease Progression. Female. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077361.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / MIB-1 antibody
  •  go-up   go-down


40. Otani N, Muroi C, Yano H, Khan N, Pangalu A, Yonekawa Y: Surgical management of tuberculum sellae meningioma: role of selective extradural anterior clinoidectomy. Br J Neurosurg; 2006 Jun;20(3):129-38
MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of tuberculum sellae meningioma: role of selective extradural anterior clinoidectomy.
  • Macroscopically complete removal with Simpson grade II was performed in 28 patients (87.5%).
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Nerve Compression Syndromes / surgery. Sella Turcica / surgery. Skull Base Neoplasms / surgery. Vision Disorders / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / methods. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801044.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Bouvier C, Liprandi A, Colin C, Giorgi R, Quilichini B, Metellus P, Figarella-Branger D: Lack of alkaline phosphatase activity predicts meningioma recurrence. Am J Clin Pathol; 2005 Aug;124(2):252-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of alkaline phosphatase activity predicts meningioma recurrence.
  • Reduced expression of the nonspecific tissue-type alkaline phosphatase (Pal) has been reported in high-grade meningiomas.
  • Pal expression was mostly altered in grades II and III meningiomas (P = .000014) and meningiomas with high MIB-1 values (P = .001).
  • [MeSH-major] Alkaline Phosphatase / biosynthesis. Biomarkers, Tumor / analysis. Meningeal Neoplasms / enzymology. Meningioma / enzymology. Neoplasm Recurrence, Local / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040297.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


42. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol; 2010 Nov;100(2):217-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
  • Prediction of recurrence remains a challenge in histopathological benign/grade I tumors.
  • Thirty-two patients were enrolled, and 23 benign non-recurrent meningiomas and 9 benign recurrent meningiomas were followed for a mean of 34 months after complete surgical resection (Simpson grades I and II).
  • Our results showed that meningioma recurrence correlated significantly with OPN IHC score (P = 0.001).
  • We concluded that OPN IHC score may play a role in prediction of the recurrence of the grade I meningiomas.
  • Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology. Osteopontin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Tissue Array Analysis. World Health Organization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2004 Feb;61(2):149-55; discussion 155-6 [14751627.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Neuro Oncol. 2010 Jan;12(1):58-70 [20150368.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):375-83 [10470810.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):135-46 [11005509.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):419-29 [12013531.001]
  • [Cites] J Cell Biochem. 2000 Jun 6;78(3):465-75 [10861844.001]
  • [Cites] J Cell Biochem Suppl. 1998;30-31:92-102 [9893260.001]
  • [Cites] Nat Rev Cancer. 2008 Mar;8(3):212-26 [18292776.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):383-8 [19330289.001]
  • [Cites] Hum Pathol. 2010 Feb;41(2):199-207 [19801161.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):63-8 [17225937.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Curr Mol Med. 2006 Dec;6(8):819-30 [17168734.001]
  • [Cites] Neuropathology. 2007 Apr;27(2):114-20 [17494511.001]
  • [Cites] Pathol Oncol Res. 2009 Jun;15(2):203-7 [19048398.001]
  • (PMID = 20428925.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


43. Choi CY, Soltys SG, Gibbs IC, Harsh GR, Jackson PS, Lieberson RE, Chang SD, Adler JR: Cyberknife stereotactic radiosurgery for treatment of atypical (WHO grade II) cranial meningiomas. Neurosurgery; 2010 Nov;67(5):1180-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife stereotactic radiosurgery for treatment of atypical (WHO grade II) cranial meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871435.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Chamberlain MC, Glantz MJ: Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer; 2008 Oct 15;113(8):2146-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
  • A phase 2 study was designed to estimate the 6-month progression-free survival of patients with recurrent, treatment-refractory, World Health Organization grade 1 meningiomas who were treated with interferon-alpha.
  • RESULTS: The most common grade 3 and 4 toxicities were fatigue (6 patients; 17%), anemia (3 patients; 8.6%), and leukopenia (3 patients; 8.6%) (toxicities were graded according to the National Cancer Institute's Common Toxicity Criteria [version 3.0]).
  • [MeSH-major] Interferon-alpha / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18756531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


45. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP: Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci; 2010 May;17(5):584-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?
  • (ii) hyperostosis of the adjacent skull;.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Male. Middle Aged. Patient Selection. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219376.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


46. Korhonen K, Parkkila AK, Helen P, Välimäki R, Pastorekova S, Pastorek J, Parkkila S, Haapasalo H: Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features. J Neurosurg; 2009 Sep;111(3):472-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrases in meningiomas: association of endothelial carbonic anhydrase II with aggressive tumor features.
  • OBJECT: Carbonic anhydrase (CA) II and IX are enzymes involved in pH homeostasis and have been shown to be upregulated in several types of cancer.
  • In this study, the authors evaluate the expression of CA II and IX in meningiomas and assess their relationship to patient age, tumor type and grade, tumor sex hormone receptor status, tumor cell proliferation, and tumor recurrence.
  • METHODS: This study was conducted in consecutive patients who underwent meningioma surgeries at Tampere University Hospital between 1989 and 1999.
  • The expression of CA II and IX was studied immunohistochemically using a tissue microarray technique and specific antibodies.
  • RESULTS: Immunohistological staining with CA II and IX was assessed in 443 primary and 67 recurrent tumor specimens.
  • Of these samples, 455 were benign (WHO Grade I), 49 atypical (Grade II), and 6 malignant (Grade III).
  • Endothelial cells in 14.8% of the tumors stained positively for CA II.
  • Endothelial CA II expression correlated with increasing histological grade (p=0.002), and tumor proliferation rates were higher in CA II+ versus CA II- cases (p=0.002).
  • Androgen receptor-negative tumors were found to be CA II+ significantly more often than androgen receptor-positive tumors (p=0.001).
  • CONCLUSIONS: Carbonic anhydrase II positivity in the endothelium was associated with cell proliferation and malignancy grade.
  • These results suggest that CA II expression is associated with malignant progression of meningiomas and could thus be a target molecule for anticancer therapy.
  • [MeSH-major] Carbonic Anhydrase II / analysis. Meningeal Neoplasms / enzymology. Meningioma / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carbonic Anhydrases / analysis. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Receptors, Androgen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216648.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


47. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


48. [What is your diagnosis? Extradural brain meningioma with rhabdoid features]. Cesk Patol; 2005 Oct;41(4):132, 169
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What is your diagnosis? Extradural brain meningioma with rhabdoid features].
  • [Transliterated title] Jaká je vase diagnóza? Extradurálny mozgový meningeóm s rabdoidnými crtami, grade II-II.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Female. Humans. Rhabdoid Tumor / pathology. Sella Turcica

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382986.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] slo
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


49. Johnson MD, O'Connell MJ, Vito F, Pilcher W: Bone morphogenetic protein 4 and its receptors are expressed in the leptomeninges and meningiomas and signal via the Smad pathway. J Neuropathol Exp Neurol; 2009 Nov;68(11):1177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The roles of bone morphogenetic proteins (BMPs) and their receptors (BMPRs) in meningioma biology are not known.
  • In this study, frozen tissues from 26 World Health Organization Grades I to III meningiomas were analyzed by Western blot for BMP-2/4, BMPR IA, and BMPR II, and activation of downstream p-Smad1, p38 mitogen-activated protein kinase (MAPK), and p44/42 MAPK signaling molecules.
  • Primary meningioma cultures from 11 meningiomas were treated with BMP-4 and evaluated for cell proliferation and signaling pathway activation.
  • Bone morphogenetic protein 4 was variably detected in adult leptomeninges but was detected in 89% or 84% of Grade I meningiomas and in 60% of Grade II meningiomas by Western blot and immunohistochemistry, respectively.
  • Bone morphogenetic protein receptors IA and II were detected in leptomeninges and in all meningiomas studied, and activated Smad1 was detected in all meningiomas studied.
  • Bone morphogenetic protein 4 stimulated meningioma cell proliferation and phosphorylation/activation of Smad1 but not p38 MAPK or p44/42 MAPK in vitro, and it was detected in conditioned media from 4 of 7 cultures.
  • These findings suggest that BMP-4 and BMPRs may play autocrine/paracrine roles and interact with other transforming growth factor-beta superfamily members in regulating meningioma growth and differentiation.
  • [MeSH-major] Bone Morphogenetic Protein 4 / biosynthesis. Bone Morphogenetic Protein Receptors, Type II / biosynthesis. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Signal Transduction. Smad Proteins / physiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation / genetics. Female. Humans. Male. Middle Aged. Transforming Growth Factor beta / metabolism. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19816200.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Morphogenetic Protein 4; 0 / Smad Proteins; 0 / Transforming Growth Factor beta; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type II
  •  go-up   go-down


50. Gao F, You T, Lü JY, Wang YJ: [Research on the expression of cancer associated gene in the intracranial tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 May;37(3):424-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Semi-quantitative RT-PCR was performed to detect the expression of CAGE gene in 17 normal tissues, 35 meningioma cases and 63 glioma cases.
  • RESULTS: The CAGE gene was expressing in none of the normal tissues except testis, but in 4 meningioma (11.3%) and 57 glioma cases(90.5%).
  • The expression of CAGE gene showed significant difference between the meningioma and glioma (P<0.001).
  • The amount of CAGE mRNA was 0.5 +/- 0.11, 0.86 +/- 0.23, 1.85 +/- 0.37 or 2.7 +/- 0.46 times of the internal control one in glioma grade I, II, or IV respectively.
  • The expression of CAGE gene increased with the pathological grade(r=0.82).
  • [MeSH-major] Brain Neoplasms / genetics. DEAD-box RNA Helicases / biosynthesis. Glioma / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Antigens, Neoplasm / biosynthesis. Antigens, Neoplasm / genetics. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761424.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 3.6.1.- / DDX53 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  •  go-up   go-down


51. Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, Saito K, Yoshida J: Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg; 2007 Aug;107(2):398-404

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to identify genes related to meningioma progression from the benign state to the atypical and anaplastic states by examining 1p LOH and the promoter methylation of RASSF1A and p73.
  • METHODS: The authors studied 40 surgical specimens (22 WHO Grade I, 11 Grade II, and seven Grade III) obtained in 37 patients with meningioma.
  • RESULTS: No 1p LOH was detected in the Grade I tumors, whereas it was detected in more than 80% of the Grade II and III tumors.
  • Methylation of the p73 promoter was observed in 81.8 and 71.4% of the Grade II and III tumors, respectively, but it was not observed in any of the Grade I tumors; methylation of the RASSF1A promoter was observed in 18.2, 63.6, and 42.9% of the Grade I, II, and III tumors, respectively.
  • Interestingly, 1p LOH and p73 promoter hypermethylation were detected in the malignantly transformed tumors but not in the lower-grade primary ones.
  • CONCLUSIONS: Based on the hypothesis that meningiomas cumulatively acquire genetic alterations and thus progress from the benign to the atypical and anaplastic states, genetic alterations in the methylation status of p73 or RASSF1A along with 1p LOH may result in the malignant transformation of a meningioma.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. DNA-Binding Proteins / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / genetics. DNA Methylation. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695396.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


52. Nowak A, Marchel A: Surgical treatment of parasagittal and falx meningiomas. Neurol Neurochir Pol; 2007 Jul-Aug;41(4):306-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningioma invaded the superior sagittal sinus in 21 cases.
  • According to Simpson's scale, 25 procedures were Grade I resection, 55 were Grade II resection and 7 were Grade IV resection.
  • Male gender, partial removal of meningioma (Simpson Grade IV) and bilateral falx meningioma had a statistically significant influence on recurrence.
  • CONCLUSIONS: Rate of recurrence of parasagittal and falx meningioma significantly increases in cases of non-radical resection of tumour.
  • [MeSH-major] Cranial Sinuses / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / methods. Postoperative Complications / prevention & control. Recovery of Function. Recurrence. Superior Sagittal Sinus / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874338.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


53. Buhl R, Nabavi A, Wolff S, Hugo HH, Alfke K, Jansen O, Mehdorn HM: MR spectroscopy in patients with intracranial meningiomas. Neurol Res; 2007 Jan;29(1):43-6
Hazardous Substances Data Bank. LACTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), we tried to get more pre-operative information in patients with suspicious meningioma concerning the histologic diagnosis especially regarding WHO Grades I and II meningiomas.
  • Within a 2 year period, 39 patients with an intracranial meningioma were studied with MRS.
  • In 62.5% of histologic atypical meningiomas (WHO Grade II), a lactate peak could be demonstrated in the pre-operative MRS.
  • [MeSH-major] Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meninges / pathology. Meningioma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Lactic Acid / analysis. Lactic Acid / metabolism. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Recurrence, Local / diagnosis. Predictive Value of Tests. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427274.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


54. Mawrin C, Perry A: Pathological classification and molecular genetics of meningiomas. J Neurooncol; 2010 Sep;99(3):379-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are extremely common adult brain tumors originating from meningeal coverings of the brain and spinal cord.
  • While most are slowly growing Word Health organization (WHO) grade I tumors, rare variants (clear cell, chordoid, papillary, and rhabdoid), as well as brain invasive (WHO grade II), atypical (WHO grade II), and anaplastic (WHO grade III) meningiomas are considerably more aggressive.
  • Early stages of meningioma tumorigenesis are closely linked to inactivation of one or more members of the 4.1 superfamily, including the neurofibromatosis type 2 (NF2) and 4.1B (DAL-1) genes, which interact with the 14-3-3 protein family.
  • Other chromosome 22q genes implicated include BAM22, BCR (breakpoint cluster region), and TIMP-1, the last of which is implicated in higher-grade meningiomas.
  • The integration of histopathological appearance, complex genetic/genomic data, and outcome will likely result in the identification of clinically distinct meningioma subgroups, which in turn can facilitate the development of targeted therapeutic strategies.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningeal Neoplasms / genetics. Meningioma / classification. Meningioma / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):135-9 [16213361.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):416-25 [15892004.001]
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] Clin Neuropathol. 2009 Nov-Dec;28(6):453-9 [19919820.001]
  • [Cites] Minim Invasive Neurosurg. 2009 Oct;52(5-6):216-21 [20077361.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):63-70 [18066497.001]
  • [Cites] Brain Res. 2010 Jun 8;1336:98-102 [20388496.001]
  • [Cites] J Neurooncol. 2010 Aug;99(1):41-8 [20094774.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):457-9 [15605995.001]
  • [Cites] J Neurosurg. 1997 May;86(5):853-8 [9126902.001]
  • [Cites] Mol Med. 2010 Jul-Aug;16(7-8):262-70 [20386868.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):43-50 [18060363.001]
  • [Cites] Cancer Genet Cytogenet. 2010 Jan 1;196(1):1-6 [19963129.001]
  • [Cites] Mod Pathol. 2004 Jun;17 (6):705-10 [15073599.001]
  • [Cites] Clin Neuropathol. 1995 Nov-Dec;14(6):327-30 [8605738.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):588-92 [18071986.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] J Pathol. 2001 Jul;194(3):367-72 [11439370.001]
  • [Cites] Neurology. 2010 Apr 27;74(17):1396 [20421586.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):129-32 [1984492.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Cancer Sci. 2009 Dec;100(12):2235-41 [19737147.001]
  • [Cites] Brain Tumor Pathol. 2009;26(2):69-72 [19856217.001]
  • [Cites] J Clin Neurosci. 2010 Feb;17(2):253-5 [20036547.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jul 15;184(2):87-93 [18617056.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Sep;54(5):698-703 [7666059.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1821-8 [17978290.001]
  • [Cites] J Neurooncol. 2010 Dec;100(3):465-73 [20454999.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Pathology. 2009;41(7):649-54 [19672786.001]
  • [Cites] Neurosurgery. 2008 Oct;63(4):771-80; discussion 780-1 [18981889.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):58-63 [3941351.001]
  • [Cites] Cancer Res. 2010 Mar 15;70(6):2350-8 [20179190.001]
  • [Cites] Brain Pathol. 2006 Jan;16(1):15-9 [16612978.001]
  • [Cites] Hum Pathol. 2010 Feb;41(2):199-207 [19801161.001]
  • [Cites] PLoS One. 2010 Jun 21;5(6):e11231 [20574529.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):314-9 [15609345.001]
  • [Cites] Brain Tumor Pathol. 2009;26(2):51-7 [19856215.001]
  • [Cites] Virchows Arch. 2010 Apr;456(4):343-54 [20165866.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3589-96 [15116094.001]
  • [Cites] Hum Mol Genet. 1994 Aug;3(8):1393-9 [7987321.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Oct;68(10):1155-65 [19918127.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):899-905 [10895812.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):218-21 [11668501.001]
  • [Cites] Brain Pathol. 2010 May;20(3):623-31 [19922547.001]
  • [Cites] Histol Histopathol. 2010 Mar;25(3):341-9 [20054806.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Am J Clin Pathol. 2001 Feb;115(2):213-8 [11211609.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):10052-9 [16260618.001]
  • [Cites] Brain Pathol. 2005 Apr;15(2):109-15 [15912882.001]
  • [Cites] J Pathol. 2006 Mar;208(4):564-73 [16353169.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):367-375 [19562258.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Nat Med. 1998 Aug;4(8):915-22 [9701243.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Cancer Invest. 2006 Dec;24(8):727-33 [17162554.001]
  • [Cites] J Neurosurg Sci. 2003 Sep;47(3):167-71; discussion 171 [14618130.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Apr 1;174(1):48-53 [17350466.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):466-71 [8057157.001]
  • [Cites] Cancer Genet Cytogenet. 2008 May;183(1):14-20 [18474292.001]
  • [Cites] Brain Pathol. 2010 Jul;20(4):751-62 [20015288.001]
  • [Cites] Mol Cancer. 2007 Oct 15;6:64 [17937814.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] Int J Oncol. 2010 Apr;36(4):983-90 [20198344.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 May;136(5):695-702 [19908067.001]
  • [Cites] Orphanet J Rare Dis. 2006 Oct 02;1:38 [17014705.001]
  • [Cites] Clin Neuropathol. 2001 Sep-Oct;20(5):190-5 [11594503.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4688-90 [18824717.001]
  • [Cites] Mol Cell Biol. 2009 Nov;29(21):5923-40 [19703993.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1482-90 [9850174.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Oct;63(10):1015-27 [15535129.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1532-6 [15489659.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] Ann Neurol. 2004 Aug;56(2):295-8 [15293284.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):391-406 [3383139.001]
  • [Cites] BMC Genomics. 2007 Jan 12;8:16 [17222329.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Hum Mol Genet. 2000 Jun 12;9(10):1495-500 [10888600.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):701-11 [11505418.001]
  • (PMID = 20809251.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


55. Liu Y, Liu M, Li F, Wu C, Zhu S: Malignant meningiomas: a retrospective study of 22 cases. Bull Cancer; 2007 Oct;94(10):E27-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant (anaplastic) meningioma constitutes a rare subset of meningioma.
  • Simpson grade I resection was achieved in 16 cases and grade II resection in 6 cases.
  • 16 patients with Simpson Grade I resection had longer median survival times than 6 patients with Simpson Grade II resection (70 months compared with 10 months, p = 0.0001).
  • Only tumor location (p = 0.016) and Simpson grade of surgical resection (p = 0.002) had an impact on outcome according to a Cox regression analysis.
  • [MeSH-major] Meningeal Neoplasms. Meningioma
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964977.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


56. Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A: Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol; 2006 Oct;32(5):525-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study we aimed at determining the relationship of basement membrane intactness and SPARC protein expression at the meningioma-brain border.
  • Sections of 51 brain-invasive meningiomas (31 meningothelial meningiomas WHO grade I, 11 atypical WHO grade II, and nine anaplastic WHO grade III tumours) were immunolabelled with antibodies against SPARC, epithelial membrane antigen (EMA), collagen IV and glial fibrillary acidic protein (GFAP).
  • Twenty-two non-invasive WHO grade I meningothelial meningiomas were included in the study for comparison.
  • By contrast, the number of WHO grade I tumours expressing collagen IV (15/31) was highly significantly elevated when compared with WHO grade II (1/11) and WHO grade III (0/9) (both P < 0.0001).
  • In conclusion, the destruction of the basement membrane is correlated with meningioma malignancy grade whereas the expression of SPARC protein at the tumour-brain border is not.
  • [MeSH-major] Basement Membrane / pathology. Brain / pathology. Brain Neoplasms / pathology. Meningioma / pathology. Osteonectin / biosynthesis. Osteonectin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Chemistry / genetics. Collagen Type IV / metabolism. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972886.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Osteonectin
  •  go-up   go-down


57. Sangoi AR, Dulai MS, Beck AH, Brat DJ, Vogel H: Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation. Am J Surg Pathol; 2009 May;33(5):669-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chordoid meningioma, World Health Organization grade II, is an uncommon variant of meningioma with a propensity for aggressive behavior and increased likelihood of recurrence.
  • A formal comparison of the immunohistochemical features of chordoid meningioma versus tumors with significant histologic overlap has not been previously reported.
  • In this study, immunohistochemical staining was performed with antibodies against D2-40, S100, pankeratin, epithelial membrane antigen (EMA), brachyury, and glial fibrillary acidic protein (GFAP) in 4 cases of chordoid glioma, 6 skeletal myxoid chondrosarcomas, 10 chordoid meningiomas, 16 extraskeletal myxoid chondrosarcoma, 18 chordomas, 22 low-grade chondrosarcomas, and 27 enchondromas.
  • Immunostaining with D2-40 showed positivity in 100% of skeletal myxoid chondrosarcomas, 96% of enchondromas, 95% of low-grade chondrosarcomas, 80% of chordoid meningiomas, and 75% of chordoid gliomas.
  • Staining with S100 demonstrated diffuse, strong positivity in all (100%) chordoid gliomas, skeletal myxoid chondrosarcomas, low-grade chondrosarcomas, and enchondromas, 94% of chordomas, and 81% of extraskeletal myxoid chondrosarcomas, with focal, moderate staining in 40% of chordoid meningiomas.
  • EMA was the most effective antibody for differentiating chordoid meningioma from skeletal myxoid chondrosarcoma, low-grade chondrosarcoma, and enchondroma, whereas D2-40 was the most effective antibody for differentiating chordoid meningioma from extraskeletal myxoid chondrosarcoma and chordoma.
  • Our findings demonstrate that in conjunction with clinical and radiographic findings, immunohistochemical evaluation with a panel of D2-40, EMA, brachyury, and GFAP is most useful in distinguishing chordoid meningioma from chordoid glioma, skeletal myxoid chondrosarcoma, extraskeletal myxoid chondrosarcoma, chordoma, low-grade chondrosarcoma, and enchondroma.
  • A lack of strong, diffuse S100 reactivity may also be useful in excluding chordoid meningioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Chordoma / chemistry. Chordoma / pathology. Immunohistochemistry. Meningeal Neoplasms / chemistry. Meningeal Neoplasms / pathology. Meningioma / chemistry. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Child. Chondroma / chemistry. Chondroma / pathology. Chondrosarcoma / chemistry. Chondrosarcoma / pathology. Diagnosis, Differential. Female. Fetal Proteins / analysis. Glial Fibrillary Acidic Protein / analysis. Glioma / chemistry. Glioma / pathology. Humans. Keratins / analysis. Male. Middle Aged. Mucin-1 / analysis. Predictive Value of Tests. S100 Proteins / analysis. T-Box Domain Proteins / analysis. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194275.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Brachyury protein; 0 / Fetal Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / S100 Proteins; 0 / T-Box Domain Proteins; 0 / monoclonal antibody D2-40; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ NIHMS775584; NLM/ PMC4847145
  •  go-up   go-down


58. Mattei TA, Mattei JA, Ramina R, Aguiar PH, Plese JP, Marino Jr R: Edema and malignancy in meningiomas. Clinics (Sao Paulo); 2005 Jun;60(3):201-6
Genetic Alliance. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Classification of the degree of edema was: level 0 edema--28 cases ; level I edema--19 cases; level II edema--8 cases.
  • Histological classification was: benign meningioma--43 cases; atypical meningiomas--11 cases; malignant meningioma--1 case.
  • CONCLUSIONS: These results suggest that the degree of edema as revealed by computer tomography and magnetic resonance imaging can be an important clinical predictive factor for the histological grade of the meningioma.
  • [MeSH-major] Brain Edema / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Severity of Illness Index. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962080.001).
  • [ISSN] 1807-5932
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


59. Caroli E, Orlando ER, Mastronardi L, Ferrante L: Meningiomas infiltrating the superior sagittal sinus: surgical considerations of 328 cases. Neurosurg Rev; 2006 Jul;29(3):236-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with meningioma involving the anterior segment of the sinus underwent total sinus resection.
  • Patients with meningioma that was infiltrating the middle and posterior third of the sinus had a complete sinus removal if the dural sinus was completely obliterated by meningioma and incomplete removal if the sinus was not occluded.
  • The tumour removal was grade I according to Simpson's grading system in 193 cases and grade II or III in the remainder.
  • [MeSH-major] Cranial Sinuses / surgery. Meningioma / surgery. Neurosurgical Procedures
  • [MeSH-minor] Activities of Daily Living. Adult. Aged. Aged, 80 and over. Angiography, Digital Subtraction. Cerebral Angiography. Disease Progression. Female. Humans. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):80-7 [5418182.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):108-11 [2589116.001]
  • [Cites] Surg Neurol. 1977 Jun;7(6):339-42 [882905.001]
  • [Cites] Neurosurgery. 1978 Sep-Oct;3(2):219-25 [360097.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Neurosurg. 1973 Feb;38(2):244-8 [4694224.001]
  • [Cites] Surg Neurol. 1984 May;21(5):427-35 [6710323.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):58-63 [3941351.001]
  • [Cites] Surgery. 1972 Jun;71(6):913-7 [5030509.001]
  • [Cites] J Neurosurg. 1994 Oct;81(4):520-4 [7931584.001]
  • [Cites] Acta Neurochir (Wien). 1992;119(1-4):91-3 [1481760.001]
  • [Cites] J Neurosurg. 1971 Oct;35(4):392-5 [5133588.001]
  • [Cites] Neurosurgery. 1997 Nov;41(5):1005-16; discussion 1016-8 [9361054.001]
  • [Cites] Acta Neurochir (Wien). 1974;30(3-4):207-15 [4611151.001]
  • [Cites] Neurosurgery. 1995 Nov;37(5):1015-8; discussion 1018-9 [8559326.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 2004 Dec;62(6):522-9; discussion 529-30 [15576120.001]
  • (PMID = 16607555.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Metellus P, Regis J, Muracciole X, Fuentes S, Dufour H, Nanni I, Chinot O, Martin PM, Grisoli F: Evaluation of fractionated radiotherapy and gamma knife radiosurgery in cavernous sinus meningiomas: treatment strategy. Neurosurgery; 2005 Nov;57(5):873-86; discussion 873-86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the respective role of fractionated radiotherapy (FR) and gamma knife stereotactic (GKS) radiosurgery in cavernous sinus meningioma (CSM) treatment.
  • METHODS: The authors report the long-term follow-up of two populations of patients harboring CSMs treated either by FR (Group I, 38 patients) or GKS radiosurgery (Group II, 36 patients).
  • There were 31 females with a mean age of 53 years in Group I and 29 females with a mean age of 51.2 years in Group II.
  • In 20 patients (Group I) and 13 patients (Group II), FR and GKS radiosurgery were performed as an adjuvant treatment.
  • In 18 patients (Group I) and in 23 patients (Group II), FR and GKS radiosurgery were performed as first line treatment.
  • RESULTS: The median follow-up period was 88.6 months (range, 42-168 mo) for Group I and 63.6 months (range, 48-92 mo) for Group II.
  • According to Sekhar's classification, 26 (68.4%) patients were Grade III to IV in Group I and 10 (27.8%) patients in Group II (P < 0.05); 23 (60.5%) patients had extensive lesions in Group I and 7 (19.4%) patients in Group II (P < 0.05).
  • Mean tumor volume was 13.5 cm in Group I and 5.2 cm in Group II (P < 0.05).
  • Actuarial progression-free survival was 94.7% and 94.4% in Group I and II, respectively.
  • Clinically, improvement was seen for 24 (63.2%) patients in Group I and for 21 (53.8%) patients in Group II (P > 0.05).
  • Radiologically, 11 (29%, Group I) patients and 19 (Group II, 52.7%) patients showed tumor shrinkage (P = 0.04).
  • Transient morbidity was 10.5% in Group I and 2.8% in Group II.
  • Permanent morbidity was 2.6% in Group I and 0% in Group II.
  • Therefore, in the authors' opinion, GKS radiosurgery should be advocated in first intention for patients with CSMs, whereas conventional radiotherapy should be reserved for cases that are not amenable to this technique, thus making these two therapeutic modalities not alternative but complementary tools in CS meningioma treatment strategy.
  • [MeSH-major] Cavernous Sinus / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Neuronavigation / methods. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284558.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Bassiouni H, Asgari S, Stolke D: Olfactory groove meningiomas: functional outcome in a series treated microsurgically. Acta Neurochir (Wien); 2007 Feb;149(2):109-21; discussion 121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A systematic investigation of long-term follow-up results after microsurgical treatment of patients harbouring an olfactory groove meningioma, particularly with regard to postoperative olfactory and mental function, has rarely been performed.
  • We reassessed a series of patients treated microsurgically for an olfactory groove meningioma in regard to clinical presentation, surgical approaches and long-term functional outcome.
  • METHOD: Clinical, radiological and surgical data in a consecutive series of 56 patients suffering from olfactory groove meningioma were retrospectively reviewed.
  • Extent of tumour resection according to Simpson's classification system was grade I in 42.9% and grade II in 57.1% of the cases.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recovery of Function / physiology. Retrospective Studies. Smell / physiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180303.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


62. Pfisterer WK, Nieman RA, Scheck AC, Coons SW, Spetzler RF, Preul MC: Using ex vivo proton magnetic resonance spectroscopy to reveal associations between biochemical and biological features of meningiomas. Neurosurg Focus; 2010 Jan;28(1):E12
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The goal in this study was to determine if proton ((1)H) MR spectroscopy can differentiate meningioma grade and is associated with interpretations of biological behavior; the study was performed using ex vivo high-resolution spectra indicating metabolic characteristics.
  • Of these meningiomas, 46 were WHO Grade I, 14 were WHO Grade II, and 8 were WHO Grade III.
  • RESULTS: The absolute concentrations of total alanine and creatine were decreased in high-grade compared with low-grade meningiomas, as was the ratio of glycine to alanine (all p < 0.05).
  • CONCLUSIONS: These data indicate that meningioma tissue can be characterized by metabolic parameters that are not typically identified by histopathological analysis alone.
  • Creatine, glycine, and alanine may be used as markers of meningioma grade, recurrence, and the likelihood of rapid recurrence.
  • These data validate a previous study of a separate group of Grade I meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Magnetic Resonance Spectroscopy / methods. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / metabolism. Meningioma / diagnosis. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine / metabolism. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Glutamic Acid / metabolism. Glycine / metabolism. Humans. Male. Middle Aged. Prognosis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043716.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3KX376GY7L / Glutamic Acid; MU72812GK0 / Creatine; N91BDP6H0X / Choline; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
  •  go-up   go-down


63. Johnson MD, O'Connell MJ, Pilcher W, Reeder JE: Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway. J Neurosurg; 2010 May;112(5):934-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary meningioma cells cultured from 10 human meningiomas were also treated with acidic FGF and evaluated for cell proliferation or activation/phosphorylation of p44/42 MAPK, Akt, and STAT3.
  • RESULTS: Immunoblotting demonstrated the presence of FGFR3 in 12 (71%) of 17 primarily fibroblastic and transitional WHO Grade I meningiomas.
  • The FGFR3 was detected in 4 (80%) of 5 WHO Grade II, and 2 of 2 Grade III tumors.
  • Acidic FGF was detected in 3 (18%) of 17 Grade I, 1 (20%) of 5 Grade II, and 1 (50%) of 2 Grade III meningiomas.
  • In WHO Grade I meningiomas, 3 of 6 tumors with no detectable FGFR3 had no detectable p-STAT3.
  • In WHO Grades II and III meningiomas, FGFR3 expression was associated with p-STAT3, p-Akt, and p-p44/42 MAPK expression.
  • No mutations were demonstrated in exons 7 or 10 by polymerase chain reaction in any meningioma.
  • Treatment with acidic FGF, a ligand for FGFR3, stimulated meningioma cell proliferation and activation of Akt and STAT3 in primary meningioma cell cultures.
  • CONCLUSIONS: These findings suggest that FGFR3 and acidic FGF are expressed in adult human leptomeninges as well as WHO Grades I and II meningiomas.
  • Fibroblast growth factor receptor-3 activation stimulates meningioma cell proliferation by activation of the phosphoinositide 3 kinase-Akt-PRAS40-mTOR and STAT3 pathways.
  • [MeSH-major] Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Cell Proliferation / drug effects. Meningioma / enzymology. Meningioma / genetics. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / genetics. Receptor, Fibroblast Growth Factor, Type 3 / genetics. Signal Transduction / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Humans. Male. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Middle Aged. Point Mutation / genetics. STAT3 Transcription Factor / genetics. STAT3 Transcription Factor / metabolism. World Health Organization

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698046.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


64. Xu YM, Qi ST, Pan J, Lu YT, Fan J: [Microsurgical removal of huge tuberculum sellae meningiomas through bi-subfrontal anterior longitudinal fission approach]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jul;30(7):1688-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among all the patients, 5 had Simpson grade I meningioma removal and the other patients had Simpson grade II removal.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Sella Turcica / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20650801.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien); 2010 Oct;152(10):1711-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate the utility of 5-ALA-induced fluorescence as a visual tool in meningioma resection and its correlation with histological findings.
  • RESULTS: A total of 32 (97%) patients presented with benign meningiomas (WHO I-II).
  • The fluorescence did not correlate with the histological findings (n = 30 WHO I-II, n = 1 WHO grade III) or with preoperative brain edema and administration of steroids.
  • CONCLUSIONS: 5-ALA-induced fluorescence is a useful and promising intraoperative tool for the visualization of meningioma tissue.
  • [MeSH-major] Aminolevulinic Acid. Fluorescence. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Monitoring, Intraoperative / methods. Photosensitizing Agents
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Recurrence, Local / prevention & control. Preoperative Care / methods. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535506.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


66. Uzüm N, Ataoğlu GA: Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification. Tumori; 2008 May-Jun;94(3):389-97
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: Meningiomas are classified following the WHO system of 2000 into three grades, benign (grade I), atypical (grade II), and anaplastic (grade III).
  • We investigated the relation between tumor grade and Ki-67 and bcl-2.
  • METHODS: In the present study, 246 cases of meningioma were reclassified according to the WHO 2000 system.
  • The relationship between tumor grade and morphological parameters like pattern, mitotic index, cellularity, pleomorphism, nucleoli, small cell population with high nucleus/cytoplasmic ratio, necrosis and brain invasion was examined.
  • There was no statistically significant difference in the prognosis between WHO grade I and grade II, whereas these two grades collectively exhibited significantly better survival than WHO grade III.
  • Ki-67 and bcl-2 expression was correlated with tumor grade, and the higher the tumor grade, the higher the Ki-67 and bcl-2 expression.
  • In conclusion, tumor grade appeared to be the most important parameter for a prognosis of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningeal Neoplasms / pathology. Meningioma / chemistry. Meningioma / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Severity of Illness Index. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705408.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


67. Rao S, Sadiya N, Doraiswami S, Prathiba D: Characterization of morphologically benign biologically aggressive meningiomas. Neurol India; 2009 Nov-Dec;57(6):744-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grade I, in general, is expected to behave in a benign fashion.
  • However, a borderline group of grade I meningioma also exists, which may behave aggressively.
  • AIMS AND OBJECTIVE: To evaluate the proliferation index and p53 antigen expression of meningiomas and correlate with histological grade and clinical course.
  • Mean Ki-67 labeling index (Ki-67 LI) was 3.8%, 13.7%, 19.4% for grade I, II, and III cases, respectively.
  • Mean p53 expression was found to be 15.5%, 57%, 60.8%, and 62.5% for grade I, II, III, and recurrent cases, respectively.
  • All recurrent cases were histologically WHO grade I, and showed a high Ki-67 LI and p53 expression with mean Ki-67 LI and p53 expression of 8.6% and 62.5% respectively.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Disease Progression. Female. Humans. Lymphocytes / metabolism. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139503.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


68. Trinkaus M, Vranic A, Dolenc VV, Lah TT: Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas. Int J Biol Markers; 2005 Jan-Mar;20(1):50-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They have a wide range of histopathological appearances and are classified, according to the aggressiveness of their growth and the risk of recurrence, as WHO grade I (benign) meningiomas, WHO grade II (atypical) meningiomas and WHO grade III anaplastic (malignant) meningiomas.
  • The expression of cathepsins B and L and their inhibitors stefin B and cystatin C in 21 benign (grade I) and 9 atypical (grade II) meningiomas has been compared by immunohistochemical staining, QRT-PCR and Northern blot analysis.
  • The expression of cathepsins and inhibitors was not different between central and peripheral meningioma tissue or between histological subtypes of meningiomas, with the exception of cathepsin L, the level of which was significantly lower in transitional meningiomas.
  • The diagnostic and prognostic value for relapse of meningioma needs to be confirmed in a larger population of patients.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsins / metabolism. Cystatins / genetics. Cysteine Endopeptidases / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / antagonists & inhibitors. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cathepsin L. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Cystatin B. Cystatin C. Disease Progression. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Progesterone / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832773.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CST3 protein, human; 0 / CSTB protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 88844-95-5 / Cystatin B; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L
  •  go-up   go-down


69. Jain D, Ebrahimi KB, Miller NR, Eberhart CG: Intraorbital meningiomas: a pathologic review using current World Health Organization criteria. Arch Pathol Lab Med; 2010 May;134(5):766-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most (47 of 51; 92%) of the tumors were WHO grade I.
  • Four tumors (8%) were WHO grade II, with 4 or more mitotic figures per 10 high-power fields, brain invasion, chordoid histology, or a combination of these features.
  • CONCLUSIONS: Intraorbital meningiomas were most frequently of the meningothelial or transitional subtypes and were WHO grade I.
  • One relatively common intracranial subtype, fibrous meningioma, was not encountered.
  • The percentage of WHO grade II tumors in the orbit (8%) is similar to that reported for intracranial tumors using the current grading scheme.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20441509.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Bassiouni H, Asgari S, Sandalcioglu IE, Seifert V, Stolke D, Marquardt G: Anterior clinoidal meningiomas: functional outcome after microsurgical resection in a consecutive series of 106 patients. Clinical article. J Neurosurg; 2009 Nov;111(5):1078-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: In this study, the authors' goal was to analyze a series of patients treated microsurgically for an anterior clinoid process (ACP) meningioma in regard to long-term functional outcome.
  • METHODS: The authors retrospectively analyzed clinical data in a consecutive series of 106 patients who underwent microsurgical treatment for an ACP meningioma at 2 neurosurgical institutions between 1987 and 2005.
  • Meningioma extensions invading the cavernous sinus, present in 29% of the patients, were not removed.
  • Complete tumor resection (Simpson Grade I and II) was achieved in 59% of the cases.
  • [MeSH-major] Meningioma / surgery. Neurosurgical Procedures. Skull Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cerebral Angiography. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / epidemiology. Tomography, X-Ray Computed. Treatment Outcome. Vision Disorders / epidemiology. Vision Disorders / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374499.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Buccoliero AM, Castiglione F, R Degl'Innocenti D, Gheri CF, Garbini F, Taddei A, Ammannati F, Mennonna P, Taddei GL: NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. Neuropathology; 2007 Feb;27(1):36-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies have indicated NF2 gene inactivation as an early tumorigenic event unrelated to the histological grade or clinical behavior.
  • The average of expression of WHO grade I and II meningiomas was higher than the average of all meningiomas, whereas that of WHO grade III meningiomas was lower.
  • When we compared the NF2 gene expression in the different meningioma grades we did not note a significant difference (P = 0.698) despite the tendency to decrease from grade I to grade III.
  • Our data supports the finding that alterations in NF2 gene alteration are histotype related but not grade related.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Expression. Gene Expression Profiling. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319281.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


72. Johnson MD, Vito F, O'Connell MJ: Mesothelin expression in the leptomeninges and meningiomas. J Histochem Cytochem; 2008 Jun;56(6):579-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The identity and functions of surface proteins on human leptomeningeal and meningioma cells are incompletely characterized.
  • Sections of 20 normal adult brains with leptomeninges and 49 World Health Organization (WHO) grade I, 21 grade II, and 2 grade III meningiomas were analyzed using an extensively characterized monoclonal antibody to mesothelin and streptavidin-biotin complex immunohistochemistry.
  • Mesothelin immunoreactivity was detected in the arachnoid in 6 of 20 cases and in 23 of 49 WHO grade I meningiomas.
  • It was also detected in 7 of 21 WHO II tumors and 1 of the 2 anaplastic meningiomas.
  • These findings suggest that mesothelin is expressed in at least some arachnoid and meningioma cells.
  • [MeSH-major] Arachnoid / metabolism. Membrane Glycoproteins / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. GPI-Linked Proteins. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21984-90 [7665620.001]
  • [Cites] Int J Cancer. 1992 Jun 19;51(4):548-54 [1351045.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):601-6 [9426397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Morphologie. 2005 Mar;89(284):22-34 [15943078.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5840-6 [16115924.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Mol Cancer. 2006;5(1):50 [17067392.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):36-42 [17319281.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1571-5 [17332303.001]
  • [Cites] Thorax. 2007 Jul;62(7):569-76 [17356060.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9055-65 [17909009.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] Respirology. 2002 Sep;7(3):171-91 [12153683.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):805-8 [8288629.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] BMC Cancer. 2004 May 12;4:19 [15140265.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • (PMID = 18347077.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ PMC2386771
  •  go-up   go-down


73. Feigl GC, Bundschuh O, Gharabaghi A, Samii M, Horstmann GA: Volume reduction in meningiomas after gamma knife surgery. J Neurosurg; 2005 Jan;102 Suppl:189-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A group of 127 patients with a mean age of 57.1 years (range 9-81 years) with 142 meningiomas (128 World Health Organization Grade I and 14 Grade II) were included in this study.
  • CONCLUSIONS: Gamma knife surgery was effective in reducing meningioma volume at short-term follow up.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662808.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Buccoliero AM, Castiglione F, Rossi Degl'Innocenti D, Arganini L, Taddei A, Ammannati F, Mennonna P, Taddei GL: Cyclooxygenase-2 (COX-2) overexpression in meningiomas: real time PCR and immunohistochemistry. Appl Immunohistochem Mol Morphol; 2007 Jun;15(2):187-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study reviews the COX-2 expression as evaluated through immunohistochemistry and real time polymerase chain reaction (RT-PCR) in 23 meningiomas [14 World Health Organization (WHO) grade I; 5 WHO grade II; 3 WHO grade III; 1 oncocytic meningioma].
  • At RT-PCR 9 meningiomas, 8 WHO grade I and 1 WHO grade II, showed a COX-2 expression greater than the reference value (average expression of all meningiomas that we studied).
  • The association between tumor grade and immunohistochemical or RT-PCR COX-2 expression was not significant (P=0.427 and P=0.251, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525632.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


75. Spektor S, Valarezo J, Fliss DM, Gil Z, Cohen J, Goldman J, Umansky F: Olfactory groove meningiomas from neurosurgical and ear, nose, and throat perspectives: approaches, techniques, and outcomes. Neurosurgery; 2005 Oct;57(4 Suppl):268-80; discussion 268-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To review the surgical approaches, techniques, outcomes, and recurrence rates in a series of 80 olfactory groove meningioma (OGM) patients operated on between 1990 and 2003.
  • Two patients, one with total and one with subtotal removal, had atypical (World Health Organization Grade II) meningiomas, whereas 78 patients had World Health Organization Grade I tumors.
  • One of them had an atypical meningioma.
  • [MeSH-major] Ear / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurosurgical Procedures / methods. Nose / surgery. Pharynx / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Craniotomy / methods. Female. Humans. Magnetic Resonance Angiography / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Skull Base / pathology. Skull Base / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234674.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


76. McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY: A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg; 2010 May;112(5):925-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Despite a favorable outcome for most patients with WHO Grade I meningiomas, a subset of these patients will have recurrent or progressive disease that advances to a higher grade and requires increasingly aggressive therapy.
  • METHODS: Records of 216 patients with WHO Grade I, II, or III meningioma that were initially treated between 1965 and 2001 were retrospectively reviewed.
  • Consequently, patients with Grade I non-skull base cranial meningiomas had better 5-year recurrence-free survival (69%) than patients with Grade I skull base meningiomas (56%) or Grade II or III tumors at any site (50%; p = 0.005).
  • Unexpectedly, patients with non-skull base tumors who experienced a recurrence (8 of 22 [36%]) were more likely than patients with skull base tumors (1 of 19 [5%]) to have a higher grade tumor at recurrence (p = 0.024).
  • Furthermore, the median MIB-1 labeling index of Grade I non-skull base cranial meningiomas (2.60%) was significantly higher than that of Grade I skull base tumors (1.35%; p = 0.016).
  • CONCLUSIONS: Cranial meningiomas that occur outside of the skull base are more likely to have a higher MIB-1 labeling index and recur with a higher grade than those within the skull base, suggesting that non-skull base cranial tumors may have a more aggressive biology than skull base tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local. Skull Base Neoplasms / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799498.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Toktas ZO, Akgun E, Ozkan A, Bozkurt SU, Bekiroglu N, Seker A, Konya D, Kilic T: Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study. Neurosurgery; 2010 Dec;67(6):1724-32; discussion 1732

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To test the relationship between the angiogenetic potential of intracranial meningiomas and clinical/prognostic features such as World Health Organization (WHO) grade, peritumoral edema, tumor border shape, and recurrence using rat corneal angiogenesis assay.
  • METHODS: Fifteen WHO grade I (typical), 10 WHO grade II (atypical), and 5 WHO grade III (malignant) meningioma samples were implanted in the micropockets formed on rat corneas, and the number of developed vessels were counted on days 5, 10, 15, and 20.
  • RESULTS: The angiogenic potential of WHO grade II tumors was significantly lower than that of grade III tumors and higher than that of grade I tumors throughout the experiment.
  • However, multivariate analysis identified WHO grade, recurrence, and peritumoral edema as significant predictors of a high angiogenic potential.
  • CONCLUSION: Our findings, based on a dynamic in vivo model to examine angiogenesis, demonstrate that the angiogenic potential of meningiomas is correlated with WHO grade, recurrence, and possibly with tumor border shape and peritumoral edema.
  • [MeSH-major] Corneal Neovascularization / etiology. Corneal Neovascularization / pathology. Meningeal Neoplasms / complications. Meningioma / complications
  • [MeSH-minor] Adult. Animals. Brain Edema / etiology. Disease Models, Animal. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Rats. Rats, Sprague-Dawley. Retrospective Studies. Time Factors. Tissue Transplantation / methods. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21107204.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Vivier J, Bardien S, Van der Merwe L, Brusnicky J, Zaharie D, Keyser R, Hewlett R, de Jong G, Hartzenberg B: A study of meningiomas in South Africa: investigating a correlation between clinical presentation, histopathology and genetic markers. Br J Neurosurg; 2009 Feb;23(1):63-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histology results showed that 86.8% of the patients had Grade I tumours and the remainder had Grade II tumours.
  • CONCLUSIONS: Our data indicate that male patients and patients with a meningioma that has 22q LOH are more likely to develop tumours exhibiting multiplicity, recurrence or calvarial erosion.
  • [MeSH-major] Chromosomes, Human, Pair 22 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Genetic Markers / genetics. Humans. Male. Middle Aged. Regression Analysis. Sex Factors. South Africa. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19234911.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


79. Scarone P, Leclerq D, Héran F, Robert G: Long-term results with exophthalmos in a surgical series of 30 sphenoorbital meningiomas. Clinical article. J Neurosurg; 2009 Nov;111(5):1069-77
Genetic Alliance. consumer health - Exophthalmos.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The authors analyzed the long-term results and radiological aspects of sphenoorbital meningioma (with emphasis on exophthalmos) in a series of 30 patients who underwent resection.
  • METHODS: Data obtained in all 30 patients who underwent surgery for typical sphenoorbital meningioma at the authors' institution between June 1994 and September 2005 were analyzed retrospectively.
  • RESULTS: Total resection (Simpson Grade I) was not achieved in these patients because of the impossibility of resecting the dura mater in the superior orbital fissure without causing significant complications.
  • Subtotal resection (Simpson Grade II) was obtained in 90% of patients, and in 3 patients (10%) a portion of the tumor was deliberately left in place because of extensive macroscopic infiltration of the cavernous sinus and/or extraocular muscles (Simpson Grade III).
  • Total resection is not possible due to superior orbital fissure invasion, but subtotal resection (Simpson Grade II) can assure long-term stability due to the nonevolutive nature of most residual tumors.
  • [MeSH-major] Exophthalmos / etiology. Exophthalmos / surgery. Meningioma / complications. Meningioma / surgery. Neurosurgical Procedures. Orbital Neoplasms / complications. Orbital Neoplasms / surgery. Skull Neoplasms / complications. Skull Neoplasms / surgery. Sphenoid Bone / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Treatment Outcome. Vision Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267523.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Colli BO, Carlotti CG Jr, Assirati JA Jr, Dos Santos MB, Neder L, Dos Santos AC: Parasagittal meningiomas: follow-up review. Surg Neurol; 2006;66 Suppl 3:S20-7; discussion S27-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Parasagittal meningioma is one that fills the parasagittal angle, with no brain tissue between the tumor and the SSS.
  • Total RF rates were 10%, 25%, and 100% at 5 years and 100%, 50%, and 100% at 10 years for patients with meningiomas WHO grades I, II, and III, respectively.
  • The RF survival curve was better for patients with grade I meningioma (grades I vs II vs III, P = .0001).
  • There was no difference between the RF survival curves according to age, histopathologic WHO grade, location along or invasion of the SSS, and extent of resection.
  • Males (P = .0401), WHO grade I (P < .0001), total resection (P = .0139), and less sinus invasion (P = .0308) had better RFS curves.
  • CONCLUSIONS: Recurrence of parasagittal meningiomas predominated in males, in grades II/III tumors, after subtotal resection, and with more invasion of the SSS.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recovery of Function. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081848.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Barresi V, Cerasoli S, Vitarelli E, Tuccari G: Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol; 2007 Aug;114(2):147-56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-four formalin fixed, paraffin embedded, surgical cases of meningiomas (WHO 28 grade I and 26 grade II) as well as ten normal leptomeningeal samples were submitted to immunohistochemical analysis for CD105.
  • CD105 was not evidenced in normal samples, whereas it was demonstrated in the vessels within 14/28 WHO grade I cases and within 24/26 WHO grade II meningiomas.
  • Higher CD105 counts were significantly correlated with higher histological grade and Ki-67 LI > 4%.
  • In conclusion, our study suggests the higher specificity of CD105 in comparison to pan-endothelial markers in the evaluation of meningioma neo-angiogenesis, and its higher prognostic significance.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neovascularization, Pathologic / pathology. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Capillaries. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594108.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


82. Sanna M, Bacciu A, Pasanisi E, Taibah A, Piazza P: Posterior petrous face meningiomas: an algorithm for surgical management. Otol Neurotol; 2007 Oct;28(7):942-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Of 139 patients with posterior fossa meningioma, 81 occurred on the posterior petrous face of the temporal bone and were the object of this study.
  • The enlarged translabyrinthine approach with transapical extension Type II was performedin 29 patients.
  • RESULTS: Total removal of the tumor (Simpson Grades I and II) was achieved in most patients (92.5%).
  • At 1-year follow-up, 46 patients (63%) had Grade I to II, 19 (26%) had Grade III, 4 (5.4%) had Grade IV, 1 (1.3%) had Grade V, and 3 (4.1%) had Grade VI.
  • CONCLUSION: Total tumor removal (Simpson Grades I-II) remains our treatment of choice and takes priority over hearing preservation.
  • [MeSH-major] Algorithms. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neurosurgical Procedures. Petrous Bone / pathology
  • [MeSH-minor] Adult. Aged. Cochlea / surgery. Ear, Inner / surgery. Facial Nerve / physiopathology. Female. Hearing Loss / etiology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Tinnitus / etiology. Vertigo / etiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721411.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Kondziolka D, Kano H, Kanaan H, Madhok R, Mathieu D, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for radiation-induced meningiomas. Neurosurgery; 2009 Mar;64(3):463-9; discussion 469-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients met criteria for a radiation-induced meningioma and underwent gamma knife radiosurgery.
  • The World Health Organization tumor grades for those with prior histology were Grade I (n = 5) and Grade II (n = 2).
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / etiology. Meningioma / surgery. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / surgery. Radiosurgery / methods. Radiotherapy, Conformal / adverse effects
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / etiology. Brain Neoplasms / surgery. Child. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240608.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Puri S, Joshi BH, Sarkar C, Mahapatra AK, Hussain E, Sinha S: Expression and structure of interleukin 4 receptors in primary meningeal tumors. Cancer; 2005 May 15;103(10):2132-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results also showed that tumors with higher disease grade tended to have increased mRNA expression for the IL-4Ralpha chain.
  • CONCLUSIONS: Expression of the IL-4Ralpha and IL-13Ralpha1 chains and absence of IL-2gammac expression established that meningiomas expressed type II IL-4Rs.
  • These receptors may serve as a target for cytotoxin/immunotoxin therapy in patients with meningioma who are not amenable to surgical resection or for recurrent tumors.
  • [MeSH-major] Meningeal Neoplasms / chemistry. Meningioma / chemistry. Receptors, Interleukin-4 / chemistry
  • [MeSH-minor] Adult. Age Factors. Brain Chemistry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Interleukin Receptor Common gamma Subunit. Interleukin-13 / chemistry. Interleukin-13 Receptor alpha1 Subunit. Middle Aged. RNA, Messenger / analysis. Receptors, Interleukin / chemistry. Receptors, Interleukin-13. Receptors, Interleukin-2 / chemistry. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830341.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL13RA1 protein, human; 0 / IL2RG protein, human; 0 / Interleukin Receptor Common gamma Subunit; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha1 Subunit; 0 / RNA, Messenger; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-13; 0 / Receptors, Interleukin-2; 0 / Receptors, Interleukin-4
  •  go-up   go-down


85. Koot RW, Stalpers LJ, Aronica E, Andries Bosch D: Cerebral necrosis after 25Gy radiotherapy in childhood followed 28 years later by 54Gy radiotherapy. Clin Neurol Neurosurg; 2007 Sep;109(7):607-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a 34-year-old patient who had prophylactic cranial irradiation with 25Gy and adjuvant chemotherapy in childhood for leukaemia and in adulthood, 28 years later, therapeutic radiotherapy with 54Gy for an atypical (WHO grade II) meningioma.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Radiation-Induced / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiation Injuries / diagnosis. Temporal Lobe / radiation effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Gliosis / pathology. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Necrosis. Radiotherapy, Adjuvant. Retreatment. Thallium Radioisotopes. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17555870.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


86. Denizot Y, De Armas R, Caire F, Moreau JJ, Pommepuy I, Truffinet V, Labrousse F: The Quantitative analysis of bFGF and VEGF by ELISA in human meningiomas. Mediators Inflamm; 2006;2006(6):36376

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The quantitative analysis of VEGF using ELISA in various subtypes of grade I meningiomas reported higher VEGF contents in meningothelial (2.38 +/- 0.62 pg/microg protein, n = 7), transitional (1.08 +/- 0.21 pg/microg protein, n = 13), and microcystic meningiomas (1.98 +/- 0.87 pg/microg protein, n = 5) as compared with fibrous ones (0.36 +/- 0.09 pg/microg protein, n = 5).
  • VEGF levels did not correlate with meningioma grade (1.47 +/- 0.23 pg/microg versus 2.29 +/- 0.58 pg/microg for 32 and 16 grade I and II, resp), vascularisation (1.53 +/- 0.41 pg/microg versus 1.96 +/- 0.28 pg/microg for 24 low and 24 high vascularisated tumours, resp), and brain invasion (2.32 +/- 0.59 pg/microg versus 1.46 +/- 0.27 pg/microg for 7 and 41 patients with and without invasion, resp).
  • [MeSH-major] Enzyme-Linked Immunosorbent Assay / methods. Fibroblast Growth Factor 2 / analysis. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Vascular Endothelial Growth Factors / analysis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Neurosurgery. 2000 Apr;46(4):938-47; discussion 947-8 [10764269.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1189-93 [7532545.001]
  • [Cites] Acta Neuropathol. 1997 Feb;93(2):109-17 [9039457.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2401-12 [9059328.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1269-77 [9179901.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):765-70 [9743297.001]
  • [Cites] J Neurooncol. 1998 Nov;40(2):123-30 [9892094.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):31-40 [15994743.001]
  • [Cites] World J Gastroenterol. 2006 Jun 21;12(23):3782-3 [16773701.001]
  • (PMID = 17392584.001).
  • [ISSN] 0962-9351
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2
  • [Other-IDs] NLM/ PMC1775028
  •  go-up   go-down


87. Sanna M, Bacciu A, Falcioni M, Taibah A, Piazza P: Surgical management of jugular foramen meningiomas: a series of 13 cases and review of the literature. Laryngoscope; 2007 Oct;117(10):1710-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Charts belonging to 13 consecutive patients with pathologically confirmed jugular foramen meningioma surgically treated between September 1991 and May 2005 were examined retrospectively.
  • Gross total tumor removal (Simpson grade I-II) was achieved in 11 (84.6%) cases.
  • Good facial nerve function (grades I and II) was achieved in 46.1% of cases, whereas acceptable function (grade III) was achieved in the remaining cases 1 year after tumor removal.
  • [MeSH-major] Glomus Jugulare Tumor / pathology. Glomus Jugulare Tumor / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / physiopathology. Ear, Inner / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Petrous Bone / surgery. Postoperative Complications. Retrospective Studies. Skull Base. Temporal Bone / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690614.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


88. Hamm K, Henzel M, Gross MW, Surber G, Kleinert G, Engenhart-Cabillic R: Radiosurgery/stereotactic radiotherapy in the therapeutical concept for skull base meningiomas. Zentralbl Neurochir; 2008 Feb;69(1):14-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other 213 patients had larger tumor volumes of up to 135 ccm or a meningioma close to optical structures.
  • Clinically significant acute toxicity (grade III) was seen in only 1 case (2.7%).
  • Some patients developed late toxicity: 8.8% had grade I, 4.4% had grade II and 1.1% had grade III.
  • [MeSH-major] Meningioma / surgery. Neurosurgical Procedures. Radiosurgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Quality of Life. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393160.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Grund S, Schittenhelm J, Roser F, Tatagiba M, Mawrin C, Kim YJ, Bornemann A: The microglial/macrophagic response at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol; 2009 Feb;35(1):82-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-three tumours were histologically WHO grade II (18, 'otherwise benign', and 15, 'otherwise atypical'), and seven, grade III.
  • Microglial/macrophagic cells were labelled with antibodies directed against major histocompatibility complex class II, CD68, CD14 and CD163.
  • RESULTS: Twenty-five per cent (10/40) meningiomas (1/18 WHO grade II 'otherwise benign', 3/15 grade II 'otherwise atypical' and 6/7 WHO grade III) contained microglial/macrophagic cells at the tumour-brain border.
  • The presence of these cells correlated with the absence of the pial-glial basement membrane (BM) and with WHO grade III.
  • CONCLUSIONS: The immune response at the tumour-brain interface correlates with the absence of the pial-glial BM and with malignancy grade.
  • [MeSH-major] Brain / immunology. Brain Neoplasms / immunology. Macrophages / immunology. Meningioma / immunology. Microglia / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, CD14 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Basement Membrane / immunology. Genes, MHC Class II. Humans. Immunohistochemistry. Middle Aged. Monocytes / immunology. Pia Mater / immunology. Receptors, Cell Surface / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187060.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / CD68 antigen, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


90. Bajetto A, Barbieri F, Pattarozzi A, Dorcaratto A, Porcile C, Ravetti JL, Zona G, Spaziante R, Schettini G, Florio T: CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro. Neuro Oncol; 2007 Jan;9(1):3-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reverse transcriptase-PCR analysis for CXCR4 and SDF1 was performed on 55 human meningiomas (47 WHO grade I, 5 WHO II, and 3 WHO III).
  • In conclusion, we found that human meningiomas express CXCR4 and SDF1 and that hSDF1alpha induces proliferation in primary meningioma cell cultures through the activation of ERK1/2.
  • [MeSH-major] Cell Proliferation. Chemokines, CXC / metabolism. Gene Expression Regulation, Neoplastic. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Chemokine CXCL12. Female. Humans. Immunoenzyme Techniques. In Vitro Techniques. Male. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Stromal Cells / metabolism. Tumor Cells, Cultured

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] Neurochem Int. 2006 Oct;49(5):423-32 [16621164.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):171-9 [15246052.001]
  • [Cites] Semin Cancer Biol. 2004 Jun;14(3):209-18 [15246057.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2348-57 [10582593.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):102-11 [10656438.001]
  • [Cites] J Neurochem. 2001 Jun;77(5):1226-36 [11389173.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7090-5 [11983855.001]
  • [Cites] Pharmacol Rev. 2002 Jun;54(2):227-9 [12037138.001]
  • [Cites] Nat Neurosci. 2002 Aug;5(8):719-20 [12080344.001]
  • [Cites] Development. 2002 Sep;129(18):4249-60 [12183377.001]
  • [Cites] J Neurochem. 2002 Sep;82(6):1311-29 [12354279.001]
  • [Cites] Neuroscience. 2002;115(1):295-305 [12401342.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1969-74 [12702590.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):635-8 [8757135.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Nature. 1998 Jun 11;393(6685):595-9 [9634238.001]
  • [Cites] Neurosci Lett. 1998 Jun 19;249(2-3):163-6 [9682842.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9448-53 [9689100.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 22;876:201-9 [10415611.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):241-53 [15921680.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):155-66 [15015781.001]
  • (PMID = 17108064.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, CXCR4; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ PMC1828107
  •  go-up   go-down


91. Roser F, Nakamura M, Bellinzona M, Ritz R, Ostertag H, Tatagiba MS: Proliferation potential of spinal meningiomas. Eur Spine J; 2006 Feb;15(2):211-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with atypical or anaplastic tumors as well as with neurofibromatosis type II were excluded from the study.
  • Furthermore both groups were matched according to age, sex and resection grade (total resection according the Simpson classification).
  • Further studies are needed to determine the role of other biological indicators in spinal meningioma growth and response to therapy.
  • [MeSH-major] Meningioma / pathology. Neoplasm Recurrence, Local / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurochirurgia (Stuttg). 1966 May;9(3):106-13 [5966658.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Neurol. 1975;208(4):279-98 [50413.001]
  • [Cites] J Neurosurg. 1987 Sep;67(3):452-5 [3612278.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] Neurosurgery. 1989 Aug;25(2):153-60 [2671779.001]
  • [Cites] Neurosurgery. 1993 Aug;33(2):212-7; discussion 217-8 [8367042.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3176-89 [7982181.001]
  • [Cites] Hum Pathol. 1996 Apr;27(4):350-4 [8617477.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:77-81 [8738502.001]
  • [Cites] Surg Neurol. 1996 Nov;46(5):458-63; discussion 463-4 [8874546.001]
  • [Cites] Surg Neurol. 1999 Dec;52(6):552-62 [10660020.001]
  • [Cites] Am J Clin Pathol. 1996 Dec;106(6):776-81 [8980354.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):241-6 [9258816.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Folia Neuropathol. 1999;37(3):179-84 [10581855.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Mar 15;25(6):727-31 [10752106.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):703-8 [10949447.001]
  • [Cites] Neurosurgery. 2001 Jan;48(1):218-21; discussion 221-2 [11152351.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):701-11 [11505418.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(4):333-40 [9689324.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1420-7 [9865827.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] Arch Pathol Lab Med. 1999 Sep;123(9):793-800 [10458826.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):80-7 [5418182.001]
  • (PMID = 15926055.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC3489402
  •  go-up   go-down


92. Mariniello G, Maiuri F, Strianese D, Donzelli R, Iuliano A, Tranfa F, de Divitiis E, Bonavolontà G: Spheno-orbital meningiomas: surgical approaches and outcome according to the intraorbital tumor extent. Zentralbl Neurochir; 2008 Nov;69(4):175-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four types were identified according to the extent of intraorbital tumor invasion: I: lateral or superolateral (15 cases); II: medial and inferomedial (8 cases); III: orbital apex (25 cases); IV: diffuse (12 cases).
  • RESULTS: Tumor removal was complete (Simpson grades I and II) in 40 cases, and incomplete in 20 (33.3%).
  • The recurrence rate was correlated with the Simpson grade of resection and the intraorbital tumor location.
  • [MeSH-major] Meningioma / surgery. Neurosurgical Procedures. Orbital Neoplasms / surgery. Sphenoid Bone
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Postoperative Complications / epidemiology. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666054.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Mattozo CA, De Salles AA, Klement IA, Gorgulho A, McArthur D, Ford JM, Agazaryan N, Kelly DF, Selch MT: Stereotactic radiation treatment for recurrent nonbenign meningiomas. J Neurosurg; 2007 May;106(5):846-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All histological sections were reviewed and reclassified according to World Health Organization (WHO) 2000 guidelines as benign (Grade I), atypical (Grade II), or anaplastic (Grade III) meningiomas.
  • Seventeen (68%) of the cases were reclassified as follows: WHO Grade I (five cases), Grade II (11 cases), and Grade III (one case).
  • The 3-year progression-free survival (PFS) rates for the Grades I, II, and III, and malignant progression groups were 100, 83, 0, and 11%, respectively (p < 0.001).
  • In the Grade II group, the 3-year PFS rates for patients treated with SRS and SRT were 100 and 33%, respectively (p = 0.1).
  • CONCLUSIONS: Stereotactic radiation treatment provided effective local control of "aggressive" Grade I and Grade II meningiomas, whereas Grade III lesions were associated with poor outcome.
  • The outcome of cases in the malignant progression group was intermediate between that of the Grade II and Grade III groups, with the lesions showing a tendency toward malignancy.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / pathology. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17542529.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Cabada T, Caballero MC, Insausti I, Alvarez de Eulate N, Bacaicoa C, Zazpe I, Tuñón T: [The role of diffusion-weighted imaging in the evaluation of meningiomas: radio-pathologic correlation]. Radiologia; 2009 Jul-Aug;51(4):411-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the histological study, cellularity, proliferation index, histological grade, and cerebral invasion were evaluated.
  • RESULTS: Of the 30 meningiomas, 22 were World Health Organization (WHO) grade I and 8 were atypical or WHO grade II.
  • The signal on the ADC map is associated with tumor cellularity but we have not demonstrated its usefulness for predicting the histological grade.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19552929.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


95. Stenstam BH, Pellettieri L, Sorteberg W, Rezaei A, Sköld K: BNCT for recurrent intracranial meningeal tumours - case reports. Acta Neurol Scand; 2007 Apr;115(4):243-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for BNCT would be even larger if recurrent grade II meningiomas could be treated, as indicated by the results of the boron uptake study.
  • [MeSH-major] Boron Neutron Capture Therapy. Brain Neoplasms / radiotherapy. Chondrosarcoma, Mesenchymal / radiotherapy. Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376121.001).
  • [ISSN] 0001-6314
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


96. Sundaram C, Uppin SG, Uppin MS, Rekha JS, Panigrahi MK, Purohit AK, Rammurti S: A clinicopathological and immunohistochemical study of central nervous system hemangiopericytomas. J Clin Neurosci; 2010 Apr;17(4):469-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 14 patients with grade II and nine with grade III tumors.
  • The mean Ki-67 labeling index was 4.25% in grade II tumors and 7.8% in grade III tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / pathology. Meningioma / pathology. Middle Aged. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20167500.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


97. Tzortzidis F, Partheni M, Voulgaris S, Gousias K, Konstantinou D: Resection of giant meningiomas of the anterior cranial fossa using orbital osteotomies. J Neurosurg Sci; 2005 Sep;49(3):77-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In all patients, total resection of the tumor (Simpson grade I, 12 patients, Simpson grade II, 8 patients) was accomplished.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Osteotomy
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288190.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


98. El Ayachi I, Baeza N, Fernandez C, Colin C, Scavarda D, Pesheva P, Figarella-Branger D: KIAA0510, the 3'-untranslated region of the tenascin-R gene, and tenascin-R are overexpressed in pilocytic astrocytomas. Neuropathol Appl Neurobiol; 2010 Aug;36(5):399-410

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also analysed a large series of various brain tumours and found that in the group of astrocytic tumours, tenascin-R expression decreased with malignancy, whereas oligodendrogliomas sometimes retained a high level of tenascin-R even in high-grade tumours.
  • [MeSH-minor] 3' Untranslated Regions / genetics. Adolescent. Adult. Aged. Child. Child, Preschool. Ependymoma / genetics. Ependymoma / physiopathology. Ganglioglioma / genetics. Ganglioglioma / physiopathology. Humans. Infant. Meningeal Neoplasms / genetics. Meningeal Neoplasms / physiopathology. Meningioma / genetics. Meningioma / physiopathology. Middle Aged. Supratentorial Neoplasms / genetics. Supratentorial Neoplasms / physiopathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202125.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Tenascin; 147604-77-1 / tenascin R
  •  go-up   go-down


99. Russell SM, Benjamin V: Medial sphenoid ridge meningiomas: classification, microsurgical anatomy, operative nuances, and long-term surgical outcome in 35 consecutive patients. Neurosurgery; 2008 Mar;62(3 Suppl 1):38-50; discussion 50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 24 patients with purely intradural tumors, four (17%) had Simpson Grade I and 19 had Simpson Grade II resections; 23 (96%) had gross total resections.
  • Of the 11 patients with tumors extending extradurally (i.e., cavernous sinus), one (9%) patient had a Simpson Grade II resection, whereas nine (82%) had Simpson Grade III resections, with the latter being all visible tumor removed except that in the cavernous sinus.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Microsurgery / methods. Neurosurgical Procedures / methods. Sphenoid Sinusitis / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Longitudinal Studies. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Neurosurgery. 2008 Jun;62(6 Suppl 3):1169-81 [18695538.001]
  • (PMID = 18424966.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Hashemi M, Schick U, Hassler W, Hefti M: Tentorial meningiomas with special aspect to the tentorial fold: management, surgical technique, and outcome. Acta Neurochir (Wien); 2010 May;152(5):827-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases were classified according to tumor extension in three different types: type I, TF meningiomas with compression of the brain stem; type II, with extension into the anterior portion of middle fossa; and type III, a combination of type I and II.
  • We defined transient and persistent operative complications in relation to Simpson grade and TF classification.
  • Extent of tumor resection was Simpson grade II in 19 patients, grade III in one patient, and grade IV in one patient.
  • Radiotherapy after volume reductive surgery in TFM type II and III and decompression of eloquent anatomical structures with low tolerance of radiation should be considered.
  • [MeSH-major] Cranial Fossa, Middle / surgery. Dura Mater / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurosurgical Procedures / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Anisocoria / etiology. Ataxia / etiology. Blepharoptosis / etiology. Cerebrovascular Disorders / etiology. Cerebrovascular Disorders / pathology. Cerebrovascular Disorders / surgery. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Cranial Nerve Diseases / surgery. Craniotomy / methods. Decompression, Surgical / methods. Diplopia / etiology. Female. Hemianopsia / etiology. Humans. Male. Middle Aged. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Radiotherapy / standards. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148271.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down






Advertisement